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IntroDuctIon
Alzheimer’s disease (AD), the most common cause of senile demen-
tia1, is characterized pathologically by the formation of amyloid 
plaques and neurofibrillary tangles in the brain2. The principal 
components of amyloid plaques are the fibrillar aggregates of amy-
loid-β (Aβ) peptides3 (39–43 amino acids), which are produced as a 
result of enzymatic proteolysis of amyloid precursor protein (APP) 
in neurons and other cells throughout life4–6. Strong circumstantial 
evidence from genetics, pathology, biochemical studies and animal 
models led to the emergence of the Aβ amyloid cascade hypothesis 
of AD7,8. This hypothesis stipulates a central role of Aβ production, 
oligomerization and/or fibrillogenesis (Fig. 1) in triggering a cas-
cade of cellular and molecular events, which lead to the develop-
ment of synaptic failure, synapse loss, neuronal loss and eventually 
dementia. Missing links between this cascade and AD pathogenesis 
include the identification of the mechanisms by which the process 
of Aβ aggregation contributes to neurodegeneration and to the 
identity of the toxic Aβ species. This knowledge is crucial for deve-
loping effective strategies to prevent and/or treat AD. Furthermore, 
the identification of specific aggregation states, which correlate 
with neurodegeneration in AD, could lead to the development of 
diagnostic tools to detect and monitor disease progression. Such 
tools are crucial for evaluating the efficacy of therapies at different 
stages of AD pathogenesis.
In solution, Aβ is unstructured, but acquires a β-sheet 
structure on aggregation and amyloid formation. Amyloid 
formation by Aβ follows a nucleation polymerization pathway 
that is characterized by an initial lag phase dominated by mono-
meric (M) species, followed by formation of low-molecular- 
weight (LMW) oligomers (dimer, trimers and  < 8-mers)9,10. 
A β-sheet–rich oligomeric ‘nucleus’ subsequently forms from 
these aggregates, which undergoes further growth to form higher-
order aggregates of heterogeneous size and morphology distribu-
tion (Table 1). These β-sheet–rich oligomeric intermediates are 
collectively referred to as prefibrillar aggregates and disappear on 
fibril formation11–13. Some of the well-documented prefibrillar 
morphologies include protofibrils (curvilinear structures less than 
200 nm in length and 4–6 nm in diameter)12–14, Aβ-derived diffus-
ible ligands (ADDLs; spherical aggregates 3–5 nm in diameter)15, 
Aβ-annular assemblies (doughnut-like structures; outer 
diameter 8–12 nm and inner diameter 2–2.5 nm)16–18 and LMW 
oligomers17,19 (Table 1). Whether some of these species repre-
sent off- or on-pathway intermediates to amyloid fibril forma-
tion remains unknown. Some of the key distinguishing features 
of protofibrillar aggregates are that they (i) contain a mixture 
of different secondary structure elements with a predominance of 
β-sheet20; (ii) bind amyloid-specific dyes, such as Congo red and 
Thioflavin-T (ThT), although less strongly than mature fibrils20–22; 
and (iii) are less stable than mature amyloid fibrils and exist in 
equilibrium with monomeric Aβ20,21,23. In the presence of mono-
meric Aβ, all these species convert to mature amyloid fibrils by 
monomer addition. Mature amyloid fibrils have been described 
as insoluble, β-sheet-rich structures that are more than 1 µm 
long, 8–12 nm in diameter and composed of 2–6 protofilament 
subunits24,25. In vitro, synthetic and recombinant forms of Aβ  
peptides have been shown to form aggregates and amyloid 
fibrils that are indistinguishable from the ones isolated from 
AD brain26–28. This suggests that the physiological process of 
amyloid formation can be recapitulated in vitro and highlights 
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the amyloid cascade hypothesis, supported by strong evidence from genetics, pathology and studies using animal models, 
implicates amyloid- (a) oligomerization and fibrillogenesis as central causative events in the pathogenesis of alzheimer’s 
disease (aD). today, significant efforts in academia, biotechnology and the pharmaceutical industry are devoted to identifying 
the mechanisms by which the process of a aggregation contributes to neurodegeneration in aD and to the identity of the toxic 
a species. In this paper, we describe methods and detailed protocols for reproducibly preparing a aggregates of defined size 
distribution and morphology, including monomers, protofibrils and fibrils, using size exclusion chromatography. In addition, we 
describe detailed biophysical procedures for elucidating the structural features, aggregation kinetics and toxic properties of the 
different a aggregation states, with special emphasis on protofibrillar intermediates. the information provided by this approach 
allows for consistent correlation between the properties of the aggregates and their toxicity toward primary neurons and/or cell 
lines. a better understanding of the molecular and structural basis of a aggregation and toxicity is crucial for the development 
of effective strategies aimed at prevention and/or treatment of aD. Furthermore, the identification of specific aggregation states, 
which correlate with neurodegeneration in aD, could lead to the development of diagnostic tools to detect and monitor disease 
progression. the procedures described can be performed in as little as 1 day, or may take longer, depending on the exact toxicity 
assays used.
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the relevance of in vitro studies for elucidating the molecular 
mechanism(s) of amyloid formation in vivo.
Several studies using familial AD (fAD) mutations in animal 
models and cell culture experiments strongly support the notion 
that early intermediates in the fibrillization process (i.e., oligomers, 
including protofibrils) are the primary toxic Aβ species and have a 
central role in AD pathogenesis. This hypothesis is supported by 
(i) the lack of a clear correlation between fibrillar amyloid burden 
in AD patients and cognitive impairment29,30, whereas such a cor-
relation has been reported for the soluble pool of Aβ (monomers 
and oligomers including protofibrils) and AD severity31,32; (ii) the 
fact that autosomal dominant mutations in APP or its cleaving 
enzymes (presenilins), which favor increased production of Aβ42 
and/or accumulation of protofibrils, are associated with the devel-
opment of fAD33–36; (iii) the indication that transgenic animals 
overexpressing fAD mutations in APP exhibit learning deficits and 
lower performance in memory tasks, compared with control ani-
mals, long before the appearance of amyloid plaques37,38; (iv) the 
fact that intracerebral administration of soluble Aβ oligomers in 
live animals impairs cognitive performance and inhibits long-term 
potentiation (LTP), a cellular model of memory formation19, and 
induces widespread plaque pathology39; and (v) the observation that 
treating cultured neurons with Aβ protofibrils results in impairment 
of ion channelss40,41, inhibition of LTP42, loss of synapses and cell 
death14. Finally, anti-Aβ antibodies specifically targeting oligomers, 
including protofibrils, block neurotoxicity in cultured neurons43 and 
reverse behavioral deficits in mice44. Therefore, there is a vast aca-
demic, medical and commercial interest in identifying therapeutic 
agents that target specifically soluble Aβ (monomers and oligomers, 
including protofibrils) and their impact on AD pathogenesis.
Studies using animal models of AD or using cultured neu-
rons suggest that prefibrillar Aβ aggregates, including LMW 
oligomers and protofibrils, exert their toxic effects by several 
potentially interrelated mechanisms, including pore forma-
tion45, channel-like activity46, permeabilization of lipid bilayers47, 
inhibition of K +  currents in cortical cultures40, disruption of 
neuronal glutamate uptake48, activation of apoptosis49, oxida-
tive damage50 and degradation of postsynaptic density marker 
PSD-95 (ref. 51). A definitive correlation of any of these biological 
effects with the development and progression of AD is not straight-
forward and remains difficult to establish. A detailed molecular 
understanding of the process of amyloid formation, as well as the 
structural properties and dynamics of the various prefibrillar inter-
mediates, is crucial for understanding the role of amyloid formation 
in AD pathogenesis. This requires access to experimental protocols 
that allow the preparation of sufficient quantities of well-character-
ized Aβ aggregate states for structural and functional studies.
Various methods have been used to prepare different oligomeric 
and protofibrillar Aβ species from synthetic Aβ (sAβ) peptides, and 
each method has its own advantages and disadvantages. Treatment 
of lyophilized Aβ with strong acids and bases to disrupt preformed 
aggregates and enhance solubility52, filtration through LMW cut-
off filters53, photo-induced crosslinking of unmodified proteins17, 
density gradient centrifugation54 and size exclusion chromatog-
raphy (SEC)13,14,17 have all been used to prepare soluble aggregates 
of Aβ and yield preparations that vary in size and morphology 
distribution. SEC, in particular, offers several advantages: (i) a 
variety of column matrices with different separation capacities 
are readily available and can be used in isolation or in combi-
nation with other columns to obtain high-resolution separation 
and fractions containing Aβ aggregates of defined size distribu-
tion; (ii) generally, the columns are equipped with filters at the 
top that allow for the removal of fibrillar (or insoluble) material 
from the injected sample, thus ensuring that the Aβ fractions are 
free of fibrillar seeds; (iii) if SEC is coupled to a light-scattering 
detector, accurate determination of Aβ aggregates’ size distribu-
tion becomes possible20; (iv) in analytical mode, SEC is a valuable 
tool to monitor early events in amyloid formation and quantifica-
tion of monomer and/or protofibril loss during the time course of 
fibril formation21; and (v) by choosing proper running conditions 
(i.e., buffer pH and contents), fractions are obtained in solution 
conditions suitable for biological systems, free of harmful or 
undesired substances (e.g., organic solvents and so on). SEC 
has also been successfully used to isolate Aβ oligomers (such as 
dimers and trimers) and high-molecular-weight aggregates 
(including protofibrils and amorphous aggregates) from complex 
cell culture media55 or from postmortem AD brain extracts56.
Although it is one of the most commonly used methods for iso-
lating and purifying Aβ oligomers13,21,23, SEC suffers from certain 
drawbacks that should be taken into consideration when using this 
technique: (i) some aggregates, because of their variable stability, 
may dissociate on interacting with column matrix and elute as LMW 
species21; (ii) there may be a low resolution of separation if the sam-
ple is composed of a continuum of interconverting aggregates of 
related sizes; (iii) the samples are diluted in concentration after SEC 
fractionation and may not be suitable for use in certain experiments 
requiring high Aβ concentration; (iv) long duration of separation 
may allow interconversion and mask changes taking place within the 
time scale of minutes or less; (v) interactions with column matrices 
and separation may also be affected by factors other than size, such 
as aggregate conformation and tertiary structure; and (vi) nonspe-
cific adsorption of hydrophobic peptides (such as Aβ) to the column 
matrix might result in a low yield of purified material.
Previous results obtained using this protocol
The early reports showing the appearance of protofibrils during the 
course of amyloid fibril formation in vitro12 heightened the interest 
in obtaining these structures in purified form13. Using SEC, sev-
eral groups showed that they can isolate protofibrillar aggregates, 
thus making it possible to elucidate their structural features and 
compare their toxicity with purified monomers or fibrils14,20. These 
studies have contributed significantly to (i) our current under-
standing of the mechanism of amyloid formation and its potential 
role in the pathogenesis of AD; (ii) our knowledge of the physical 
and structural properties of different oligomeric and protofibrillar 
Aβ species; and (iii) the development of important research tools 
1 2 3 4
Figure 1 | A fibril formation pathway. (1) A monomers, under favorable 
conditions, can aggregate to form non-fibrillar and fibrillar aggregates. The 
non-fibrillar aggregates, based on their molecular size and/or morphology, 
can range from low-molecular-weight (LMW) oligomers (n = 2–8) (2) to 
highly ordered structures such as protofibrils and A-derived diffusible 
ligands (ADDLs) (3). The non-fibrillar aggregates can be ‘on pathway’ (solid 
arrows) to fibril formation and disappear upon fibril formation (4), or  
‘off-pathway’ (dashed arrows with a cross) species (that is, they do not 
convert into fibrils). Structures are not drawn to scale.
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table 1 | Glossary of Aβ aggregation.
term Description references
Amyloid Extracellular, insoluble proteinaceous deposits (plaques) that are composed primarily of fibrillar  
aggregates comprising a single protein (Aβ in the case of AD-linked amyloid). Amyloid is defined by  
its dye-binding properties: increased fluorescence and green birefringence with Thioflavin-T and  
Congo red, respectively. In addition to the fibrillar protein, amyloid deposits contain other proteins,  
glycosaminoglycans and proteoglycans
87,88
Fibril Filamentous structure, consisting of 2–6 protofilaments, seen in cross-sections from disease-affected  
tissue and also observed during aggregation of synthetic Aβ peptides in vitro. Mature fibrils are  
characterized by: (i) cross-β X-ray fiber diffraction pattern; (ii) β-sheet rich CD and FTIR spectra;  
(iii) binding to Congo red and Thioflavin-T and (iv) characteristic filamentous morphology (8–12 nm in 
diameter,  > 1 µm long) by AFM and TEM imaging (Figs. 3f and 4h). Depending on the solution and  
incubation conditions, a given protein sequence can yield fibrils of diverse morphologies
25,27,89,90
Protofilament Structural subunit of a mature fibril. Appear as twisted thread with a characteristic periodicity  
and helical arrangement. (Note: different from protofibril (see below))
25,91,92
Oligomers The term ‘oligomers’ encompasses a wide range of species, ranging from low-molecular-weight (LMW)  
species (including dimers, trimers and tetramers) to high-molecular-weight (HMW) oligomeric species  
(such as spherical, chain-like and annular structures or longer structures (Fig. 4e–g)). Fibrils are, by 
definition, protein oligomers. Different types of oligomeric species have been described and are typically 
distinguished by their composition, stability and molecular weight
13,15,17–19
LMW oligomers Generally, LMW oligomer preparations contain a mixture of species that are less than 8-mers and are in 
equilibrium with monomeric Aβ, as determined by denaturing SDS-PAGE gels or cross-linking studies. 
These species are generally not detectable by standard TEM techniques. The smallest Aβ oligomer species 
that could be visualized and its size determined by STEM was of 42–80 kDa. Evidence for the LMW  
oligomers has been primarily derived from denaturing SDS-PAGE electrophoresis experiments and cross-
linking studies. There is no evidence that these species accumulate in a stable form. Furthermore, the 
possibility that these oligomers could be derived from HMW oligomers has not been ruled out
17–19
SDS-stable  
LMW oligomers
SDS-resistant LMW oligomers ( < 8-mers) have been prepared in vitro or isolated from natural sources  
(cell cultures or brain tissues). LMW oligomers that are secreted from CHO cells overexpressing wild-type 
APP, or APP bearing fAD mutations, exhibit strong stability to SDS and chemical-induced dissociations, 
whereas the majority of LMW oligomers generated in vitro by separation through a SEC column are SDS 
sensitive, unless stabilized by chemical cross-linking. Naturally secreted LMW oligomers were shown to 
inhibit LTP and impair cognitive performance when injected into rat brains at much lower concentration 
than that used to observe toxicity with synthetic Aβ. However, despite extensive efforts by different 
laboratories to establish the chemical identity and true stoichiometry of naturally formed SDS-stable 
oligomers/aggregates by mass spectrometry, such data remain lacking and current size estimates are 
solely based on their mobility in denaturing gels
17,19,68
High molecular 
weight
Metastable Aβ heterogeneous oligomers that can be visualized by TEM and AFM and range in size from  
~42 kDa to  > 1 mDa
12,13,15,16, 
18,20,21,93
 • Protofibrils Metastable, heterogeneous, -sheet rich prefibrillar structures that have been observed by AFM and TEM 
during amyloid fibril formation. Different protofibril preparations of Aβ reveal heterogeneous mixtures of 
discrete β-sheet aggregates of different sizes (50–1,500 kDa) and morphologies (spherical (5–20 nm), 
annular structures and smooth, curvilinear structures (5 nm in diameter and  < 200 nm in length)). TEM  
and AFM studies support a structural link between some of these different aggregates, but the mecha-
nisms by which they form, the dynamics of their interconversion and their relationship with the amyloid 
fibrils remain poorly understood. Although protofibrils were initially thought to be on the linear pathway 
to fibrils, in its current usage, this term embraces all prefibrillar aggregates (≥4 nm) that can be detected 
by EM and AFM. Protofibrils bind to Congo red and Thioflavin, although to a lesser extent than mature 
fibrils. Therefore, protofibrils here are kinetic intermediates, whereas protofilaments (see definition given 
above) represent the substructure of the amyloid fibril
12,20,21
 •ADDLs Globular structures of 3–5 nm in diameter. Also referred to as globulomers. Initial reports, using mainly 
AFM and denaturing SDS-PAGE electrophoresis, suggested that these preparations contain primarily small 
oligomers ~10–12-mers. However, subsequent solution characterization of the ADDL preparations showed 
that they consist of a heterogeneous population of A species, encompassing molecular sizes ranging 
from monomers to aggregates larger than 1 mDa, resembling the distribution observed for protofibrils
15,67,83
(continued)
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(such as conformational antibodies) and of novel amyloid-based 
diagnostic tools and therapeutic strategies.
Structural and mechanistic studies. The ability to purify pro-
tofibrils in sufficient quantities has facilitated biophysical and 
structural studies aimed at characterizing their structure and 
toxic properties. Biophysical studies, using multiple techniques, 
on SEC-purified Aβ protofibrils revealed many important struc-
tural and physical features that distinguish these species from 
monomeric and fibrillar forms of Aβ. Aβ protofibrils were shown 
to (i) bind amyloid-specific dyes such as Congo red and ThT18,20,21; 
(ii) be enriched with a β-sheet structure20; (iii) possess a core struc-
ture protected from solvent20,21,23; and (iv) exist in equilibrium with 
monomeric Aβ20,21,23. Quasielastic light-scattering measurements 
revealed that SEC-purified Aβ protofibrils contained aggregates 
with hydrodynamic radii (R
H
) of 10–50 nm, which correspond to 
lengths of ~30–500 nm for noninteracting rods13. The heterogene-
ity of protofibrils was further elucidated by scanning transmission 
electron microscopy (TEM)18 and sedimentation velocity measure-
ments57. These studies revealed that protofibrils are a population 
of aggregates with molecular weight distribution ranging from 
80 kDa to ~1 mDa (ref. 23).
Previous studies have established the ratio of Aβ40 to Aβ42 as 
an important factor in determining the fibrillogenesis, toxicity and 
pathological distribution of Aβ in vivo58–60. The ability to obtain 
monomeric and protofibril preparations of Aβ42 and Aβ40 by 
SEC allowed us to characterize the interactions between these two 
peptides at the levels of monomers, protofibrils and fibrils. This 
approach also enabled us to investigate how these interactions and 
changes in the relative ratio of Aβ42/Aβ40 influence Aβ oligomeri-
zation and fibrillogenesis in vitro. We showed that monomeric 
Aβ40 is a potent inhibitor of monomer Aβ42 amyloid formation 
at 1:1 ratio, whereas it inhibits fibrillization by Aβ42 protofibrils 
at substoichiometric amounts21. Furthermore, we found that Aβ42 
protofibrils seed the fibrillization of monomeric Aβ42 but not of 
monomeric Aβ40. In contrast, fibrils composed of either Aβ42 or 
Aβ40 seeded the fibrillization of both Aβ42 and Aβ40 monomers21. 
Using these purified preparations, we were also able to show that 
monomeric Aβ42 and Aβ40 are constantly recycled and compete for 
binding to the ends of protofibrillar and fibrillar Aβ aggregates21.
Finally, using the same monomer and protofibril preparations 
referred to above, we dissected the mechanism by which the heat 
shock protein (Hsp104) interferes with Aβ oligomerization and 
fibrillogenesis. These studies revealed that Hsp104 inhibits Aβ 
fibrillization, targets different intermediates on the amyloid path-
way and suppresses the seeding capacity of Aβ42 protofibrils and 
fibrils by blocking their growth61.
Identifying the toxic Aβ species and elucidating the mechanism 
of toxicity. A critical challenge in understanding the mechanism 
of Aβ toxicity, and in the subsequent design of intervention strate-
gies, has been the correlation of a particular aggregate structure or 
size with biological effects, especially toxicity. Initially, fibrils were 
reported to be toxic, and inhibition of fibril formation or disrup-
tion of fibrils was considered to be a viable strategy for inhibiting 
Aβ toxicity62–64. Subsequent studies, using SEC-purified protofibrils 
and monomers, showed that protofibrils exhibit stronger toxicity 
than monomeric and fibrillar Aβ14,20,21.
Together, these seminal studies showed that Aβ40 protofibrils 
consistently impaired neuronal metabolism20, instantly altered 
neuronal electrical activity and induced cell death14,21. SEC-purified 
monomeric Aβ, in contrast, had no effect on neuronal electrical 
activity14 and required 3–5 d of incubation to induce quantifi-
able cell injury14. This observation suggested that some aggrega-
tion intermediates, formed during the incubation of monomeric 
Aβ, were responsible for inducing toxicity. These findings were 
corroborated by studies in which cultured neurons were treated 
with monomers of highly amyloidogenic Aβ sequences, Aβ42 and 
Aβ40-Arctic. The results showed that the treated neurons exhib-
ited loss of processes within 7 h and cell death within 13–24 h of 
incubation with monomeric Aβ42 and Aβ40-Arctic65. Similarly, 
using SEC-isolated Aβ42 protofibrils, we have shown that mono-
meric Aβ40 inhibited Aβ42 protofibril toxicity toward cultured 
neurons by altering their aggregation properties and inhibiting 
fibril formation. These observations reinforced the importance 
of an ongoing Aβ-nucleated polymerization as a critical factor 
for Aβ-induced toxicity21,66.
Size exclusion chromatography has also been used to characterize 
the relative toxicity of different Aβ protofibril preparations and has 
improved our understanding of the nature of toxic species in such 
preparations. ADDLs are soluble Aβ aggregates that, by atomic force 
microscopy, appear as spherical structures of 3–5 nm in diameter15. 
SEC was used to fractionate ADDLs and different fractions were 
compared for binding to the neuronal surface67. Results showed 
that void volume ( > 70 kDa) fractions selectively bound to the cell 
surface and processes of neurons. No such binding was reported 
table 1 | Glossary of Aβ aggregation (continued).
term Description references
 • Annular  
oligomers
Doughnut-shaped structures that have an outer diameter of 8–12 nm and inner diameter of 2–2.5 nm 16,18
Nucleus A rare unstable entity (such as LMW oligomers and protofibrils) that influences the rate of a nucleated 
polymerization process. Nuclei are metastable in nature; they can form and act as seeds (see below) for 
growth of a fibril or possibly disassemble, thus reducing the fibril growth
21,89,94
Seed A relatively stable entity (such as fibrils and fragmented fibrils), which, when introduced into a solution 
containing monomeric subunits, serve as effective nuclei and accelerate fibril formation (by eliminating 
the lag phase associated with nuclei formation) in a nucleation polymerization process
9,95
Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; ADDL, Aβ-derived diffusible ligand; AFM, atomic force microscopy; APP, amyloid precursor protein; CD, circular dichroism; CHO, Chinese hamster ovary; 
EM, electron microscopy; fAD, familial AD; FTIR, Fourier transform infrared; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; STEM, scanning transmission electron microscopy;  
TEM, transmission electron microscopy.
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for fractions containing monomers to tetramers, suggesting that 
advanced oligomer states, protofibrils, are more likely to be the cul-
prit toxic species in ADDL preparation67. Subsequent solution-state 
characterization of ADDL preparations revealed that they consist of 
a heterogeneous population of Aβ species encompassing molecular 
sizes ranging from monomers to aggregates larger than 1 mDa, 
resembling the distribution observed for protofibrils.
In addition to sAβ oligomers, SEC has also been used to elu-
cidate the nature of toxic Aβ oligomers obtained from natural 
sources. The conditioned media of Chinese hamster ovary cells, 
stably expressing Val-717Phe fAD mutation in APP, contain mon-
omeric and LMW oligomeric forms of Aβ68. SEC was used to 
separate the monomers from oligomers and then fractions were 
used to assess the effects of both species on learning and memory-
related tasks in rats. Intracerebroventricular injections into rats 
with fractions containing oligomers, but not monomers, were 
associated with significant errors in the behavioral performance 
of animals69. Transgenic (Tg 2576) mice, harboring the Swedish 
mutation in APP (APPSWE) linked to fAD, exhibit signs of mem-
ory deficits at the age of 6–14 months without accumulation of 
plaques or neuronal loss. Sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and SEC analysis of brain 
extracts from 6- to 14-month-old mice 
revealed that soluble multimers of Aβ, 
particularly a 56-kDa species and to lesser 
extent a 40-kDa species, correlated with 
the onset of memory deficit and remained 
stable during this time70. The 56-kDa spe-
cies (Aβ*56) was then purified by SEC and 
injected into the lateral ventricles of young 
healthy rats. Assessment of spatial mem-
ory task performance revealed that Aβ*56 
induced transient memory impairment in 
treated rats without affecting the learning 
of new tasks70. Thus, the use of SEC in the 
studies cited above allowed the investiga-
tors to selectively identify particular Aβ 
oligomers (dimers and trimers or Aβ*56) 
as the most likely cause of behavioral defi-
cits observed in animal experiments.
Generation of novel tools and 
therapeutics. SEC-based methods, or 
information garnered from these methods, 
have also been useful for elucidating the 
mechanism of action of novel diagnos-
tic and therapeutic approaches for AD. 
Immunizing rabbits with soluble oligo-
mers of synthetic Aβ mimics resulted in 
the generation of an antibody that selec-
tively reacted with Aβ oligomers in dot blot 
assays71. The antibody did not react with 
LMW or fibrillar preparations, suggesting 
conformation specificity for oligomers. 
SEC fractionation of Aβ oligomers and 
subsequent dot blot assay with an oli-
gomer-specific antibody showed that the 
smallest oligomer size detected by the anti-
body corresponded to a 40-kDa protein71. 
Interestingly, the antibody also showed binding to oligomeric prep-
arations of other amyloidogenic sequences such as α-synuclein and 
human insulin, suggesting a molecular conformation shared by 
oligomeric intermediates of these proteins. Most importantly, the 
antibody was not only able to discriminate between AD-affected 
and normal brain but also distinguished thioflavin-S–positive 
(fibrillar) aggregates from non-thioflavin-S–binding (oligomeric) 
aggregates in AD-affected brain71. Similarly, immunization of mice 
with ADDLs led to the generation of monoclonal antibodies that 
selectively reacted with oligomeric SEC fractions of ADDLs and 
not with monomeric fractions. Immunostaining of brain sections 
or dot blots on brain extracts by these antibodies showed their 
ability to discriminate AD-affected from normal brain72.
Experimental design
The general procedure for isolating monomeric and protofi-
brillar Aβ fractions, and subsequent elucidation of their bio-
physical and biological properties, is outlined in Figure 2. To 
prepare monomeric Aβ fractions, the lyophilized peptide is 
dissolved and disaggregated by guanidine hydrochloride treat-
ment65,73, and then the solution is injected into a suitable SEC 
column to separate Aβ monomers from guanidine (Table 2). 
Aβ wild-type or mutant peptide
Aβ solubilized
Centrifuged
Step 1
Step 2, Fractions collected (and concentration adjusted)
Step 3–14, Biophysical characterization
Steps 3–4
TIMING
Step
1
2
3 –4
5–10
11–14
15–17
Description Approximate time
Fractionation by SEC ~3– 4 h (~15 –20 min solubilization, ~1–2 h column equilibration,
~1–2 h fractionation)
By UV spectrophotometry ~10 min,
by BCA ~45 min
~1 h for one sample
~10 min (for one time point)
~1 h–5 d (depending on the assay used)
~20 min for one sample (~5 min for preparing the grid and ~15 min
for image acquisition
Analytical SEC (Ana-SEC)
TEM
ThT binding
Assessment of toxicity in
neuronal cultures
Aβ concentration determination
Analytical SEC Thioflavin-T Morphologic changesCell death
Steps 5–10
Electron microscopy
Steps 11–14
Step 15–17, Biological characterization
Size-exclusion chromatography
Aβ protofibrils
peak
Monomer Aβ
peak
Figure 2 | Flow diagram illustrating steps and approximate timeline for A fractionation by SEC and 
subsequent biophysical and/or biological characterization.
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This procedure yields fractions that are highly enriched (≥90%) 
in monomeric Aβ. Although these preparations are free of 
protofibrillar or fibrillar aggregates, the presence of unstable 
LMW oligomers (dimers, trimers, and so on) that are in rapid 
equilibrium with the major monomeric species has been sug-
gested and cannot be ruled out. To prepare protofibrillar Aβ 
fractions, the peptide is initially dissolved in DMSO57 and then 
aggregation is promoted under high-salt conditions. This leads 
to the generation of a solution enriched with Aβ protofibrils and 
monomers. The different aggregation states and monomers are 
separated on a suitable SEC column (Table 2). Often, these aggre-
gation parameters can be assessed and customized by monitoring 
the degree of monomeric versus protofibrillar Aβ elution from 
the column. After a defined interval of incubation, if needed, the 
peptide solution is centrifuged to pellet out fibrils or insoluble 
material. The supernatant is then injected into a suitable SEC 
column capable of carrying out separation in a defined molecular 
size range, and Aβ species are eluted from the column under iso-
cratic conditions. To avoid unwanted Aβ aggregation during the 
separation procedure, it is recommended that SEC fractionation 
be carried out using a chromatography system placed inside a cold 
(4 °C) chamber. Alternatively, SEC can be carried out at room 
temperature (RT; 20–25 °C) provided that Aβ solutions are kept 
at 4 °C before injection and immediately transferred to 4 °C after 
eluting from the column. Fractions are then assessed for protein 
content and subsequently used for biophysical and/or biological 
studies. Biophysical studies may include further separation by 
SEC, characterization of the kinetics of fibril formation (such as 
ThT binding) and the structural and morphological properties 
of aggregates by imaging techniques such as electron microscopy 
and atomic force microscopy. For biological experiments, SEC 
monomeric or protofibrillar fractions are diluted by the addition 
of cell/tissue culture (TC) components needed for maintaining 
the osmolarity, pH and nutritive value of the media. Monomeric 
and protofibril fractions at high concentrations (50–100-µM) are 
desired for these experiments. This can be achieved by scaling 
up the peptide preparation or using a modified or concentrated 
cell/TC media. Preparation of Aβ fractions at higher concen-
trations, by scaling up the amount of injected peptide, is pos-
sible only up to a certain concentration: 2–3 mg ml − 1 for slow 
aggregating Aβ sequences (e.g., Aβ40), but not for highly amy-
loidogenic Aβ peptides such as Aβ42 or the Arctic variant of both 
Aβ40 and Aβ42. At high concentrations of  > 1–2 mg ml − 1, the 
latter peptides start to fibrillize within minutes and precipitate, 
thus reducing the overall yield of monomers and protofibrils. 
Hence, a modified TC recipe for culturing primary neurons with 
concentrated components has been devised to minimize the 
dilution of Aβ fractions (Table 3). With tissue components added, 
table 2 | Fractionation range of SEC columns and Aβ42 fractions obtained after SEC.
serial no.

sec column
separation range for  
globular proteins (kDa)
protofibrillar  
fractions (ml)
Monomer  
fractions (ml)
1 Superdex 75 HR 10/30 3–70 2 (7–9) 2 (11–13)
2 Superose 6 HR 10/30 5–5,000 4–6 (6–11) 2 (14–16)
Abbreviation: SEC, size exclusion chromatography.
table 3 | Preparation of modified neurobasal components.
component composition
Inorganic salts (100×) mg per 10 ml H2O
 CaCl2•2H2O 264
 KCl 400
 MgCl2•6H2O 162
 NaH2PO4 108
Amino acids (100×) mg per l H20
 Alanine 20
 Arginine HCl 840
 Asparagine•H2O 83
 Cysteine 121
 Glutamine 735
 Glycine 30
 Histidine•HCl•H2O 420
 Isoleucine 1,050
 Leucine 1,050
 Lysine HCl 1,460
 Methionine 300
 Phenylalanine 660
 Proline 77.6
 Serine 420
 Theronine 950
 Tryptophan 160
 Tyrosine 720
 Valine 940
Vitamin solution (100×) mg per l H20
 NaCl 8,500
 D-Ca pantothenate 100
 Choline chloride 100
 Folic acid 100
 I-Inositol 200
 Nicotinamide 100
 Pyridoxal HCl 100
 Riboflavin 10
 Thiamine HCl 100
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various neurotoxicity studies can be conducted. Lactate dehydro-
genase (LDH) release or MTT (3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide) assays can be used to measure 
overt cell loss (Step 17A) or histological staining for subtle morpho-
logical changes using cytoskeletal markers (Step 17B) can also be 
carried out. Electrophysiological measurements on cultured cells 
or brain slices were shown to provide a highly sensitive and instan-
taneous readout of neuronal abnormalities caused by the addition 
of specific Aβ aggregates, but require expensive equipment and 
specialized expertise, and will not be discussed in this paper14. 
Finally, biological activity can also be assessed in commercial 
cell lines of neuronal origin such as PC12 and SHSY5Y cells. In 
this case, modified commercial TC media (such as 10× Dulbecco’s 
modified Eagle’s medium) are commercially available and can 
be used to avoid further dilution of Aβ fractions.
Although SEC has been used to obtain monomeric and pro-
tofibrillar forms of Aβ, the yield of the respective fractions may 
vary depending on the peptide sequence and the presence of 
preformed seeds in lyophilized peptide stock. It is known that Aβ 
peptides from different manufacturers, or even different lots from 
the same source, may yield inconsistent aggregation and toxicity 
results74. The approach outlined in this protocol ensures that 
the recovered peptide fractions are free of any fibrillar material 
and variability among different Aβ preparations is minimized. 
Finally, to circumvent any potential problems associated with 
the use of sAβ peptides (such as impurities, racemization, salts 
or trace metals introduced during peptide synthesis and puri-
fication52), many laboratories have developed methods for the 
expression of recombinant Aβ (rAβ) in E. coli75–77. rAβ peptides 
have been shown to exhibit similar or higher toxicity compared 
with sAβ75,76. In addition to being free of any impurities associ-
ated with sAβ, which might interfere with aggregation or toxicity, 
rAβ peptides also offer an inexpensive means of obtaining radio-
isotope-labeled Aβ for structural studies using NMR75,76.
The present protocol, principally based on the use of SEC, describes 
methods for generating monomeric, protofibrillar and fibrillar forms 
of Aβ40 and Aβ42, using sAβ and rAβ peptides and fAD mutants 
(e.g., Aβ40-Arctic and Aβ40-Dutch) prepared with different counteri-
ons (trifluoroacetate (TFA) or sodium hydroxide) and obtained from 
different commercial suppliers and academic research groups.
MaterIals
REAGENTS
Human wild-type (wt) synthetic Aβ42-wt, Aβ40-wt and fAD mutants 
(Aβ40-Arctic (E22G), Aβ40-Dutch (E22Q) and Aβ40-Flemish (A21G)). 
These were synthesized and purified as TFA salts by Dr. James I. Elliott,  
WM Keck Facility, Yale University, New Haven, CT, USA, as previously  
described78  crItIcal Aliquot the lyophilized peptide in glass vials, seal 
with a tight wrapping of parafilm and store the aliquots at  − 20 °C. Before 
use, bring the peptides to RT by leaving the vial in a dry place for 10–15 
min. Do not remove the parafilm wrapping except just before weighing and/
or solubilization (see Step 1 of PROCEDURE). It is recommended to store 
the vials in a box containing a desiccant (EM Sciences, cat. no. 71225-00)  
for this purpose.
DMSO (Sigma, cat. no. 41639)  crItIcal DMSO is hygroscopic and 
should be stored in a dry place.
Tris (hydroxymethyl)-aminomethane (Tris-base; Sigma, cat. no. T1503)
Trizma hydrochloride solution (Tris-HCl, 1 M; Sigma, cat. no. T2663)
Hydrochloric acid (32% (wt/vol) Merck, cat. no. 1.00319.1000) ! cautIon 
It is extremely corrosive and toxic and readily produces toxic vapors. Use a 
fume hood, face mask, eye protection and gloves while handling.
Sodium hydroxide solution (NaOH, 1 N; Sigma, cat. no. 59223C)  
! cautIon It is extremely corrosive and toxic. Use a fume hood, face mask, 
eye protection and gloves while handling.
Guanidine hydrochloride (Gn-HCl; Sigma, cat. no. G4630) ! cautIon It is 
toxic and an irritant.
Uranyl acetate (UA; Electron Microscopy Sciences, cat. no. 22400)  
! cautIon It is a radioactive chemical, toxic if inhaled or ingested and  
it is categorized as a suspected carcinogen. Wear gloves, eye protection and 
face mask while handling.
Thioflavin-T (ThT; Sigma, cat. no. T3516)
Glycine (Sigma, cat. no. 50046)
Bicinchoninic acid (BCA) protein assay kit (Pierce, cat. no. 23227)
DMEM (1×, high glucose without glutamine and sodium pyruvate;  
Invitrogen, cat. no. 11960-051)
Hank’s buffered salt solution (HBSS; Invitrogen, cat. no. 14185052)
(4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES, 1 M;  
Invitrogen, cat. no. 15630-080)
PBS (GIBCO, cat. no. 10010-015)
Sorensen’s phosphate buffer (0.15 M; Electron Microscopy Sciences,  
cat. no. 11682-10)
F-12 nutrient mixture (Invitrogen, cat. no. 11765-054)
B-27 supplement (Invitrogen, cat. no. 10889-038)
Neurobasal medium (Invitrogen, cat. no. 10888-022)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
FBS (GIBCO, cat. no. 10101145)
Penicillin-streptomycin (Pen-strep, 100×; GIBCO, cat. no. 15140-122)
Poly-l-lysine, 331 (MW 331 k; Sigma, cat. no. P-1524)
Laminin (Sigma, cat. no. L2020)
Trypsin-EDTA (Invitrogen, cat. no. 25200-056)
l-Glutamine (200 mM; GIBCO, cat. no. 25030)
Inorganic salts (100×; Table 4)
Amino acids (100×; Table 4)
Vitamin solution (100×; Table 4)
Lactate dehydrogenase cytotoxicity assay kit (Cayman chemical, cat. no. 
10008882). It contains LDH diaphorase, NAD +  (100×), lactic acid  
(100×), LDH standard, cell-based assay buffer tablet, LDH (tetrazolium salt 
(INT) (100×)).
Mouse monoclonal microtubule-associated protein-2 antibody  
(MAP-2; Sigma, cat. no. M2320)
Rabbit polyclonal neurofilament-M (NF-M) antibody (Millipore,  
cat. no. AB1987)
Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, cat. no. A-11001)
Alexa Fluor 594 donkey anti-rabbit IgG (Invitrogen, cat. no. A-21207)
4′,6-Diamidino-2-phenylindole, dihydrochloride (DAPI; Invitrogen,  
cat. no. D1306)
ProLong Gold antifade reagent with DAPI (Invitrogen, cat. no. P36931)
EQUIPMENT
Tabletop centrifuge (Eppendorf, model no. 5417R) with adjustable  
temperature and speed controls
Vortex genie 2 (Scientific Industries, model no. G560E) or other suitable 
vortexing equipment
ÄKTAexplorer fast protein liquid chromatography (FPLC; GE Healthcare) 
or any other chromatography system equipped with a UV detector and  
a fraction collector
Carry 100-Bio UV spectrophotometer (Varian) or any other UV-VIS  
spectrophotometer
Microcell (10-mm pathlength; Varian, part no. 6610010400) or appropriate 
microcell for UV-VIS spectrophotometry
Size exclusion chromatography (SEC) column, Superdex 75 HR 10/30  
(GE Healthcare, cat. no. 17-1047-01; 1 column volume (CV)  =  24 ml)
SEC column, Superdex 75 pc 3.2/30 (GE Healthcare, cat. no. 17-0771-01;  
1 CV  =  2.4 ml)
SEC column, Superose 6 HR 10/30 (GE Healthcare, cat. no. 17-0537-01;  
1 CV =  24 ml)
SEC column, Superose 6 pc 3.2/30 (GE Healthcare, cat. no. 17-0673-01;  
1 CV  =  2.4 ml)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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Sample loop, PEEK (1 ml; GE Healthcare, cat. no. 18-1114-01)
PEEK tubing (i.d. 0.75 mm; GE Healthcare, cat. no. 8-1112-53)
Standard 1.5-ml plastic micro test tube or equivalent (low protein binding) 
(Eppendorf 3810×; Eppendorf, cat. no. 0030 125.150)
Sterile microtubes (Fisherbrand, cat. no. 05-669-27)
HPLC separation module (2795) with PDA detector (Waters) for analytical 
SEC (Ana-SEC) or any other chromatography system for high-sensitivity 
measurements
A Philips CM10 transmission electron microscope (TEM; Philips) equipped 
with a Morada CCD camera or other TEM setup with image acquisition 
equipment
Formvar/carbon-coated TEM grids (Electron Microscopy Sciences,  
cat. no. FCF200-Cu-50)
Grid storage box (Electron Microscopy Sciences, cat. no. 71140)
High-precision ultrafine tweezers (Electron Microscopy Sciences,  
cat. no. 78318-3X)
Parafilm (Milian, cat. no. ARA-994)
Cell culture plates (96-well; BD Falcon, cat. no. 353072)
Cell culture plates (24-well; BD Falcon, cat. no. 353047)
Plates, black (384-well; Nunc, cat. no. 262260)
Glass coverslips (12-mm) or coverslips that use German-made glass  
(Carolina Biological Supplies, cat. no. BA-62-4734)
Microdissection forceps (Carolina Biological Supplies, cat. no. 633009)
HERAcell incubator (Thermo Scientific, model. no. 150) or any other  
appropriate cell culture incubator (37 °C, 5% CO
2
 and 100% humidity)
Precision incubator (Memmert, model no. INB 400) or any other  
temperature-controlled incubator
Fluorescence microplate reader (Analyst AD; Molecular Devices)
Absorbance microplate reader (Safire 2; TECAN)
Stericup-GP polyethersulfone (PES) filtration unit (0.22 µm, 500 ml;  
Millipore, cat. no. SCGPU05RE)
UV/Vis photometer (Eppendorf, cat. no. 6132000.008)
Microcuvette (Eppendorf, cat. no. 0030106.300)
Synthetic Aβ42 (as TFA salt; Bachem, cat. no. H-1368)
rAβ peptides (rPeptides, cat. no. A-1002-2 (for TFA salt) and cat. no.  
A-1165-2 (for NaOH salt))
Syringe filter (PES) (0.22 µm; TPP, cat. no. 99722); PVDF or cellulose filter 
media can also be used for filtering buffers and solutions
REAGENT SETUP
Running buffer for preparative and Ana-SEC Add 10 ml of 1 M Tris-HCl 
(pH 7.4) to 990 ml of ultrapure H
2
O. Filter and degas the solution with a vac-
uum-driven Stericup-GP 0.22-µm PES filtration unit.  crItIcal Prepare fresh 
buffer each time. For most of the biophysical studies, Tris buffer can be used 
with the addition of 0–70 mM NaCl. However, Tris is toxic to neurons, and thus 
HEPES is used for cell-based assays (70 mM NaCl  +  10 mM HEPES (pH 7.4)).
Guanidine hydrochloride solution (6 M) Dissolve 5.8 g of guanidine hydro-
chloride (analytical grade) in 5 ml of ultrapure H
2
O by continuous vortexing 
until a visibly clear solution is achieved. Bring the solution’s final volume to 
10 ml and store at 4 °C.  crItIcal Bring the solution to RT before use by 
leaving the solution on a bench for ~5–10 min. Wear gloves while handling. 
 pause poInt The solution can be stored at 4 °C for 2–3 months. Presence 
of precipitates warrants immediate disposal.
Tris base solution (2 M; pH 7.6) Dissolve 2.2 g of Tris base in 10 ml of 
ultrapure H
2
O and mix until a visibly clear solution is achieved. Bring the 
pH to 7.6 with dropwise addition of 32% HCl and with continuous mixing. 
Filter the solution with a 0.22-µm PES syringe filter.  pause poInt The 
solution can be stored at 4 °C for 2–3 months. The presence of precipitates 
warrants immediate disposal.
UA solution (2% (wt/vol)) Dissolve 200 mg of UA in 10 ml of ultrapure 
H
2
O and vortex until a particulate-free solution is achieved. Filter the  
solution using a syringe-driven 0.22-µm PES filter and store at 4 °C. 
  pause poInt The solution should be prepared as needed and can be 
stored at 4 °C for 1 month.  crItIcal Dispose of the solution as per  
institutional regulations. Wear gloves while handling.
ThT solution (100-M) Dissolve 0.32 mg of ThT in 10 ml of ultrapure H
2
O 
until a particulate-free solution is achieved. Filter the solution using a  
0.22-µm PES syringe filter.  pause poInt Aliquot the volume needed for 
the day (Step 12) and store the rest at 4 °C. The solution can be stored at 4 °C 
for 2–3 months. The presence of precipitates warrants immediate disposal.  
 crItIcal Protect from light by wrapping the tube in aluminum foil.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Glycine-NaOH solution (500 mM; pH 8.5) Dissolve 376 mg of glycine in 
10 ml of ultrapure H
2
O until clear. Bring the pH to 8.5 by adding 1 N NaOH 
while continuously mixing. Filter the solution with a 0.22-µm PES syringe 
filter and store at 4 °C.  pause poInt Remove the volume needed for the 
day (Step 5), and store the rest at 4 °C for up to 2–3 months. The presence of 
precipitates warrants immediate disposal.
EQUIPMENT SETUP
Equilibration of SEC columns Connect the appropriate SEC column  
(Table 2) to an ÄKTAexplorer FPLC or any other equivalent chromatographic 
table 4 | Ordering information of the components for modified 
Neurobasal media.
component supplier catalog no.
Inorganic salts
 CaCl2•2H2O VWR EM-CX013-1
 KCl VWR JT3040-1
 MgCl2•6H2O VWR JT2444-1
 NaH2PO4, anhydrous VWR JT3821-1
Amino acids in acid
 Isoleucine Sigma-Aldrich I7403
 Leucine Sigma-Aldrich L8912
 Phenylalanine Sigma-Aldrich P5482
 Tryptophan Sigma-Aldrich T8941
 Tyrosine Sigma-Aldrich T8566
Amino acids in H2O
 Alanine Sigma-Aldrich A7469
 Arginine HCl Sigma-Aldrich A6969
 Asparagine•H2O Sigma-Aldrich A7094
 Cysteine Sigma-Aldrich C7352
 Glutamine Sigma-Aldrich G8540
 Glycine Sigma-Aldrich G8790
 Histidine•HCl•H2O Sigma-Aldrich H5659
 Lysine•HCl Sigma-Aldrich L8662
 Methionine Sigma-Aldrich M5308
 Proline Sigma-Aldrich P5607
 Serine Sigma-Aldrich S4311
 Theronine Sigma-Aldrich T8441
 Valine Sigma-Aldrich V0513
Vitamin solution Invitrogen 1087845
 NaCl
 D-Ca pantothenate
 Choline chloride
 Folic acid
 I-Inositol
 Nicotinamide
 Pyridoxal HCl
 Riboflavin
 Thiamine HCl
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system, equipped with a UV detector and a fraction collector. Equilibrate 
the column with 10 mM Tris-HCl (pH 7.4) at a flow rate of 0.5 ml min − 1. 
 pause poInt The columns should be equilibrated with at least two CVs 
or more (~50 ml for HR 10/30 columns) until a flat baseline UV signal is 
achieved. For carrying out Aβ fractionation, it is highly recommended to use 
a chromatography system placed in a 4 °C chamber. Alternatively, Aβ frac-
tionation can still be carried out at RT, provided fractions are immediately 
transferred to ice (within 5–10 min of eluting from the column).  
 crItIcal For toxicity studies, the column is equilibrated with 70 mM 
NaCl  +  10 mM HEPES (pH 7.4). The amount of NaCl used can vary from  
0 to 70 mM as desired. Test the pH of the eluant to ensure that a pH between 
7.2 and 7.6 is obtained. All Aβ preparations and column solutions used for 
cell culture experiments should be processed to maximize sterility. For stor-
age and sterilization, columns should always be completely washed with 20% 
ethanol; for cleaning and sterilizing, the columns should be washed with  
0.5 M NaOH solution (refer to the column data sheets provided by the  
manufacturer, for cleaning procedures). The columns can be operated at  
a higher flow rate (up to 1 ml min − 1), provided the maximum operational 
pressure, as recommended by the manufacturer, is not exceeded.
Equilibration of Superdex 75 or Superose 6 pc 3.2/30 columns for Ana-SEC  
Connect the Superdex 75 pc 3.2/30 or Superose 6 pc 3.2/30 column to  
the FPLC placed in a 4 °C chamber. Equilibrate the column with two CVs  
(~5 ml for pc 3.2/30 columns) of 10 mM Tris-HCl (pH 7.4) at a flow rate of 
0.05 ml min − 1.  crItIcal Set the high pressure limit to 2.4 MPa (Superdex 
75 pc 3.2/30) or 1.2 MPa (Superose 6 pc 3.2/30) to avoid damaging the 
column matrix. Cleaning and storage should be carried out as recommended 
by the manufacturer. Flow rate can be increased up to 0.1 ml min − 1, provided 
the maximum operational pressure, as recommended by the manufacturer,  
is not exceeded.
Neuronal toxicity studies Obtain cortical neurons from E16 mouse embryos 
(Box 1). Add the cells in plating medium (Table 5) to poly-L-Lysine-coated 
glass coverslips or plastic 24-well plates (Box 2) at a density of ~2.5 × 105 
cells per 0.4 ml per well. Place the plates in a cell culture incubator under  
conditions of high humidity, 37 °C and 5% CO
2
. On day 2, fully replace the 
media with neuronal growth media (Table 5) and return the plates to the  
37 °C incubator.  pause poInt Healthy cells should start to develop  
processes within 24 h of plating and interconnectivity should be observed 
2–3 d after plating.
proceDure
1| Fractionation of Aβ by SEC (Fig. 2) ● tIMInG ~ 3–4 h
(a) obtaining the monomeric form of various a peptides, including a40 and a42
 (i)  Dissolve 1 mg of Aβ in 1 ml of 6 M guanidine hydrochloride and mix until a visibly clear solution is achieved. 
 crItIcal step By careful visual inspection, ensure that no precipitates are present and almost all of the lyophilized 
peptide has been dissolved in the solvent. 
 pause poInt The vial/tube with the peptide can be centrifuged (3,000g at RT for 1 min) before solubilization to 
bring the lyophilized peptide to the bottom of the vial/tube and minimize peptide loss.
 (ii) Centrifuge the solution (16,000g for 10 min at 4 °C) in a tabletop centrifuge.
 (iii)  Carefully draw the supernatant into a 1-ml syringe for subsequent injection for SEC (see below). 
 crItIcal step Avoid taking pelleted material into the syringe, as it will cause pressure problems if injected into 
the SEC column.
 (iv)  Inject the supernatant, obtained from Step 1A(iii), into a Superdex 75 HR 10/30 SEC column, using a 1-ml sample loop. 
 crItIcal step Ensure that the column is equilibrated with appropriate running buffer, as outlined in EQUIPMENT 
SETUP above.
 (v)  Fractionate Aβ at a flow rate of 0.5 ml min − 1 with the individual fraction size being 1 ml. 
 crItIcal step Set upper operational pressure limit to 1.8 MPa. 
? troublesHootInG
 (vi)  Collect and combine the two fractions under elution peak at 11–13 ml (0.45–0.55 CV of the Superdex 75 HR 10/30 
column). The combined fractions represent monomeric Aβ. 
 crItIcal step Immediately transfer the fractions to ice or keep at 4 °C, but do not freeze or leave at RT (if SEC is 
carried out at RT).
(b) obtaining protofibrillar a42 (or a40-arctic and a40-Dutch mutants)
 (i)  Dissolve 1 mg of Aβ in 50 µl of 100% DMSO. Carefully mix with pipette to avoid introducing air bubbles. 
 crItIcal step By careful visual inspection, ensure that no precipitates are present and that all of the lyophilized 
peptide has been dissolved in the solvent. To avoid Aβ fibrillization, do not spend more than 30–60 s on this step. 
 pause poInt To ensure maximal peptide recovery, the peptide vial/tube can be centrifuged (3,000g at RT for  
1 min) before adding the DMSO, collecting all of the lyophilized peptide at the bottom of the vial/tube.
 (ii) Add 800 µl of ultrapure H2O and carefully mix with a pipette.
 (iii)  Immediately add 10 µl of 2 M Tris-base solution (pH 7.6) and vortex briefly (2–5 s). 
 pause poInt This procedure leads to the formation of a mixture of monomer and protofibrillar Aβ42 in solution; 
however, the amount of protofibrils formed varies from 50–80% depending on the batch of the peptide and  
solubilization efficiency. To maximize the amount of protofibrils, incubate the solution at RT for 1–5 min.
 (iv)  Carry out centrifugation and SEC fractionation as described in Steps 1A(ii–v) above. 
 pause poInt Aβ protofibrils elute in the void volume (~7–9 ml of elution volume for HR 10/30 columns) and 
monomeric fractions elute similarly as mentioned in Step 1A(vi).
 (v)  Combine the two fractions under void volume elution peak (7–9 ml of elution volume) and label as protofibrils. Sepa-
rately combine the two fractions under elution peak at 11–13 ml (0.45–0.55 CV of the Superdex 75 HR 10/30 column) 
and label as monomeric Aβ. 
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 Box 1 | DISSECTING CEREBRAL CoRTEx NEURoNS 
1. Purchase Swiss Webster, time-pregnant mice (Taconic or Charles River) ~E15–16.
 pause poInt This age is optimal for removing meninges, and neurons are predominately postmitotic. Younger and older animals  
are more difficult to dissect because of problems in removing meninges.
2. Prepare three 60-mm sterile Petri dishes with 3 ml of ice-cold dissection medium (table 2) and place on ice.
 pause poInt Keeping the brain ice cold during dissection improves the recovery of healthy neurons and keeps the brain  
architecture intact, facilitating microdissection.
 crItIcal step Prepare in tissue culture (TC) hood.
3. Prepare two 35-mm sterile Petri dishes with 1 ml of dissection medium (table 2) and place on ice.
 crItIcal step Prepare in TC hood.
4. Mice are killed under the guidelines of the Institution’s Animal Care Committee and according to local governmental regulations.
5. After killing the pregnant mouse, place the animal on a clean disposable dipper, ventral side up, and wet down the animal’s fur with 
70% ethanol.
6. Using a pair of sterile scissors and forceps, cut the abdominal skin along the midline and retract skin to the right and left side.
7. Rinse any fur from the abdominal muscles with 70% ethanol and use a second pair of sterile scissors to cut the abdominal muscles  
and peritoneum along the midline. Retract the abdominal walls to expose the uterus carrying the embryos, which will be readily  
observable.
8. Pull out the uterus after cutting the connective tissue and vasculature and transfer to a sterile 100-mm Petri dish placed on ice.
 crItIcal step When picking out the uterus containing embryos, do not grab and puncture the intestines, which might pose a risk 
of infecting the embryos with bacteria.
 pause poInt The intact uterus can be removed in a chain-like manner containing all embryos (on an average 8–12 embryos in a 
Swiss Webster mouse). In the following steps, transfer brain tissue to successive sterile dishes to reduce the possibility of bacterial 
contamination.
9. Dissect out the individual embryos by cutting open the uterus and amniotic sacks.
10. Using scissors, cut the head off at the neck region directly into the prepared 60-mm dish containing ice-cold dissection medium 
placed on ice.
11. Under a dissection microscope at ×2 magnification, cut the skin and the developing cranium (membranous and not calcified at this 
stage) along the midline.
 crItIcal step Do not cut into the underlying neocortical surfaces.
 pause poInt Less distortion of the brain increases the success of the microdissection.
12. With the brain exposed, scoop out the brain using fine forceps starting at the olfactory bulbs and moving posteriorly.
 pause poInt A pair of forceps is used to disconnect the cranial nerves and lift the brain out as one moves posteriorly. The brain is 
removed intact and placed into the next clean 60-mm dish containing ice-cold dissection medium. Repeat this process for each of the 
remaining brains.
13. Transfer one brain into a 35-mm dish with ice-cold dissection medium and remove the meninges. The meninges (easily visible 
because of their vascularity) are removed as a continuous sheet by grabbing with the tips of the fine forceps and peeling over the front 
of the brain and then back toward the brainstem.
 crItIcal step Removing the meninges is an important step to avoid fibroblast contamination of cultures.
14. Using forceps and starting at the fissure between the two hemispheres, roll out the medial part of one hemisphere to reveal the 
hippocampus.
 pause poInt The hippocampus is at the medial interface of the upper surface of the neocortex and appears as a rostral–caudal 
curved tubule.
15. Using fine forceps, cut along the neocortex–hippocampus interface and remove the hippocampus.
 pause poInt The hippocampus removed at this stage can be used to prepare hippocampal cultures.
16. With the hippocampus removed and the neocortex rolled a little further laterally, cut with the fine forceps at the underlying 
neocortex (light, lateral area)–striatum (dark, medial, striated structure) interface. Repeat this step for each side and place the two 
cortical hemispheres into new 35-mm dishes with ice-cold dissection medium.
 pause poInt The process of isolating each cerebral cortex from each brain is continued and all hemispheres are combined.
17. Carefully remove as much of the dissection medium as possible and then add 1 ml of Trypsin-EDTA, mince with forceps and incubate 
for 10 min at 37 °C to activate Trypsin.
 pause poInt Trypsin is kept cold before addition to minimize self-inactivation. In addition, Trypsin is frozen as 1-ml aliquots,  
allowing only the amount needed to be thawed for each dissection.
 crItIcal step The repeated freezing and thawing of Trypsin, especially at 37 °C, will continually reduce the effectiveness of this 
protease.
18. While trypsinizing tissue, narrow the opening of a sterile glass Pasteur pipette by flaming the tip.
 crItIcal step Do not narrow it too much.
19. Slowly triturate the trypsin-containing cortices through the pipette until a homogenous suspension is achieved.
20. Transfer the triturated tissue (should be around 1 ml) to a sterile 15-ml tube and add 1 ml of plating medium containing serum  
to inhibit the trypsin. The tissue and medium solutions are mixed with the trituration pipette.
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 crItIcal step Immediately transfer the monomeric and protofibrillar fractions to ice or keep at 4 °C, but do not 
freeze or leave at RT (if SEC is carried out at RT).
(c) obtaining protofibrillar a40
 (i)  Dissolve Aβ40 at a concentration of 1 mM (4.3 mg ml − 1, based on the total weight of the peptide) in 1 mM NaOH plus 
sterile phenol red (0.1 mg ml − 1 to monitor the pH of the solution). The final pH of this solution is ~3. 
 crItIcal step By careful visual inspection, ensure that no precipitates are present and that all of the lyophilized 
peptide has been dissolved in the solvent. 
 pause poInt The vial/tube with the peptide can be centrifuged (3,000g at RT for 1 min) before solubilization to 
bring the lyophilized peptide to the bottom of the vial/tube and minimize peptide loss.
 (ii)  Add 140–155 µl of 10 mM NaOH per mg of peptide. 
 crItIcal step To minimize isoelectric precipitation of Aβ (pI ~5.5), which can vary between manufacturers and 
specific lots, 10 mM NaOH is added to achieve a rapid transition to a pH of ~7.0–7.5. This can be visualized by orange 
to red color change, when phenol red is used as the pH indicator. 
 pause poInt Additional acid or base can be added to achieve the proper pH.
 (iii)  Dilute the peptide with sterile water and then with 10× PBS to yield a final concentration of 500 µM peptide in 1× PBS 
(70 mM NaCl, 1.35 mM KCl and 5 mM NaH2PO4/Na2HPO4 (pH ~7.4)).
 (iv)  Incubate the solution at RT for 2–3 d to generate protofibrils and monomers of Aβ40. 
 pause poInt The progression of the aggregation can be checked periodically by injecting small amounts of the 
mixture to observe the monomer to protofibril ratio.
 (v)  Carry out centrifugation and SEC fractionation as described in Step 1A(ii–v) above.
 (vi)  Combine the two fractions under void volume elution 
peak (~7–9 ml of elution volume for the HR 10/30 
columns) and label as protofibrils. Separately combine 
the two fractions under elution peak at 11–13 ml 
(0.45–0.55 CV of the Superdex 75 HR 10/30 column) 
and label as monomeric Aβ. 
 crItIcal step Immediately transfer the monomeric 
and protofibrillar fractions to ice or keep at 4 °C,  
but do not freeze or leave at RT (if SEC is carried out 
at RT).
(D) sec for subfractionating protofibrils
 (i)  Centrifuge the Aβ peptide solution (16,000g for  
10 min at 4 °C) obtained from Step1B(iv) and inject 
the supernatant, using a 1-ml sample loop, into a  
Superose 6 HR 10/30 SEC column.
 (ii)  Fractionate at a flow rate of 0.5 ml min − 1, with the 
individual fraction size being 1 ml. 
 crItIcal step Set upper pressure limit to 1.5 MPa.
 (iii)  Collect four 1-ml fractions, corresponding to the 
elution volume of 6–11 ml, which contain the total 
protofibril peak, and do not combine. The monomer 
fractions (elution volume 14–16 ml) can be combined. 
 crItIcal step Immediately transfer the fractions 
to ice or keep at 4 °C, but do not freeze or leave at RT 
(if SEC is carried out at RT). 
 pause poInt Fractionation efficiency can also be 
increased by connecting two SEC columns in series 
(such as two Superose 6 HR 10/30 columns or a 
21. Count the cells using a hemocytometer.
 pause poInt Cells can be incubated with trypan blue before counting to determine the ratio of live to dead cells. Trypan blue is 
excluded from viable cells.
22. Finally, dilute the cells for plating in the plating media (table 2) at a density of 2.5 × 105 cells per 0.4 ml per well, then add to 
poly-l-lysine-coated 24-well plates or poly-l-lysine  +  laminin-coated coverslips (box 2). Place plated cells into an incubator at 37 °C.
 Box 1 | CoNTINUED
table 5 | Media for dissection and culture of neuronal cells.
component Volume (ml)
Dissection medium 500
 5 ml of 1 M HEPES 5
 5 ml of 1 M glucose 5
 5 ml of 1 M sucrose 5
 50 ml of 10× Hank’s salt 50
 Cell culture–grade H2O 435
Plating medium 500
 1× DMEM (without glutamine) 50
 FBS 50
 F-12 50
 1 M HEPES 10
 Glutamine 5
 Pen-strep (100×) 5
 H2O 330
Growth medium for neuronal cultures 100
 Neurobasal medium 98
 B-27 2
Abbreviations: HEPES, (4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid; Pen–Strep,  
Penicillin–streptomycin.
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TSK4000 SEC column connected in series to Superose 6 HR 10/30). However, in the latter case, to obtain Aβ fractions 
at concentrations above 20 µM, 1.5–2 mg ml − 1 peptide should be solubilized for fractionation.
concentration determination
2| The protein concentration of the fractions can be determined by different methods depending on the instrumentation 
available and desired accuracy. Aβ concentration can be determined by measuring absorbance at 280 nm using a UV spec-
trophotometer or any of the commercially available protein assays (such as BCA assay). Both of these methods are readily 
available, but may contain marginal error. For measurements requiring high precision, amino-acid analysis (AAA) is recom-
mended. The latter method requires sending the samples to a specialized facility, and requires a few hours/days to complete. If 
information regarding the absolute concentration of Aβ fractions is critically needed, we recommend using one of the methods 
described below to determine the concentration for short-term reference, and sending some of the original solution for AAA. If 
the concentration determined by AAA is different from that determined by UV or BCA, the latter is then corrected accordingly. 
We have carried out a comparison of these methods for measuring Aβ concentrations and the findings are summarized in  
box 3. box 3 also contains some assay-related information for UV A280 nm and BCA, in the context of Aβ concentration estimations.
(a) using uV spectrophotometry ● tIMInG ~10 min
 (i)  Stabilize the light source of the spectrophotometer by turning on the lamp for ~10–15 min before its use. Obtain  
the UV absorbance of SEC running buffer (10-mM Tris-HCl (pH 7.4)), at wavelength (λ) 280 nm (A280), by placing  
100 µl of the buffer in a 10-mm-path-length cell. Set the reading of the spectrophotometer to zero using the  
unadulterated running buffer. Thereafter, obtain UV absorbance at λ280 nm for the different Aβ fractions.
 (ii)  Calculate the molar concentration of Aβ fractions by dividing A280 values by the factor of 0.0015 (box 4).
 (iii)  Adjust the concentration of individual fractions as appropriate for desired biophysical studies (10–20 µM for  
Steps 3, 5 and 11) or as appropriate for biological assays (Step 15) in SEC running buffer. 
 pause poInt For neuronal toxicity studies, refer to table 6 for sample preparation.
(b) using bca method ● tIMInG ~45 min
 (i)  For generation of a standard curve, dissolve 1 mg ml − 1 of lyophilized Aβ40 (200 µM, based on dry weight) in  
high-purity H2O by continuous vortexing. 
 crItIcal step Aliquot 200 µl of this stock Aβ solution per tube and store at  − 20 °C until needed. Use sterile 
tubes (Fisherbrand, cat. no. 05-669-27). Avoid repeated freezing and thawing of the peptide solution. Thaw the stock 
solution on ice. 
 pause poInt Most of the sAβ is provided as peptide content of ~80% by dry weight. Check the peptide content 
from the Aβ supplier and adjust accordingly.
 (ii) Prepare the ‘working reagent’ (WR) provided in the BCA kit (follow manufacturer’s instructions).
 (iii)  Using Aβ40 stock (200 µM), prepare 50 µl of Aβ40 protein at standard dilutions of 5, 10, 20, 30, 40, 50, 75, 100, 150 
and 200 µM in high-purity H2O for generating a standard curve.
 (iv)  In a clear-bottomed 96-well microplate, add 200 µl of WR to wells that will receive either unknown Aβ samples or Aβ 
standards.
 (v)  Add 25 µl of each Aβ standard to the appropriate well already containing WR. 
 crItIcal step Use H2O as blank control. 
 pause poInt Each standard concentration should be tested with a minimum of duplicates.
 Box 2 | CoATING CoVERSLIPS AND 24-WELL PLASTIC PLATES 
Neurons are plated onto either 24-well plastic plates for biochemical evaluation of cell viability or onto glass coverslips for histological 
observations.
1. Sterilize coverslips with 100% ethanol for a minimum of 2 h or overnight in a sealed sterile dish.
 crItIcal step Do not use 70% ethanol, which will lead to coverslips being difficult to separate and potential breakage.
2. After sterilization, suction off ethanol and air-dry the coverslips in a sterile environment (e.g., in a TC hood).
3. Place one coverslip per well; a 12-mm coverslip fits into the well of a 24-well plate.
 crItIcal step Low evaporation plates are necessary to minimize the liquid loss in the outside wells.
4. Prepare substrate solution to coat glass coverslips by combining poly-l-lysine (PLL) (MW 331K)  +  laminin solution. To obtain  
10 ml of substrate solution, add 1 ml of PLL solution (1 mg ml − 1) and 0.1 ml of laminin solution (1 mg ml − 1) to 8.9 ml sterile,  
high-quality water.
 pause poInt Laminin is not needed if coating is carried onto plastic surfaces.
5. Add 300 µl to each well containing a coverslip (requiring 7.2 ml per 24-well plate). Wrap plates in aluminum foil and incubate 
overnight at RT.
6. Next day, wash plates three times with sterile water and then air-dry in TC hood.
 pause poInt Plates that are not used immediately can be stored at 4 °C, properly wrapped in aluminum foil.
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 (vi)  Add 25 µl of each Aβ sample of unknown protein concentration to the appropriate well already containing WR. 
 crItIcal step Use SEC running buffer as a blank control. 
 pause poInt Each sample should be tested using a minimum of duplicates.
 (vii) Cover the plate and incubate at 37 °C for 30 min.
 (viii)  Read the absorbance at λ562 nm. 
 pause poInt If a microplate reader is not available, a suitable UV/Vis photometer (for example Eppendorf, cat. no. 
6132000.008) can also be used. For this purpose, use a microcuvette (such as Eppendorf, cat. no. 0030106.300) to 
read each sample and proceed as outlined below.
 (ix)  Subtract H2O absorbance values from the standards and SEC running buffer absorbance from Aβ samples. 
 pause poInt This step is required only if BCA is performed using a microplate reader.
 (x)  Determine the concentration of Aβ in each fraction (µM) from the standard curve using Microsoft Excel or any other 
suitable software.
 (xi)  Adjust the concentration of individual fractions as appropriate for desired biophysical studies (e.g., 10–20 µM for 
Steps 3, 5 and 11) or as appropriate for biological assays (Step 15) in SEC running buffer. 
 pause poInt For neuronal toxicity studies, refer to table 6 for sample preparation.
analytical sec ● tIMInG ~1 h for one sample
3| Inject 50 µl of each Aβ fraction (protofibrils and monomer) into a Superdex 75 pc 3.2/30 SEC column connected to a 
Waters 2,795 separation module or any other chromatography system with high-sensitivity detectors.
 Box 3 | CoMPARISoN oF UV A280 nm,  BICINCHoNINIC ACID (BCA) ASSAY AND 
AMINo-ACID ANALYSIS (AAA) FoR DETERMINATIoN oF A CoNCENTRATIoN 
We have outlined two commonly available methods of protein concentration determination, namely UV A280 and BCA, in Step 2 of this 
protocol. However, the following points are worth mentioning in the context of Aβ concentration estimations:
1. UV A280: The method relies on the molar absorbance coefficient for a particular protein (box 4). Theoretically, the concentration of 
monomeric protein can be reliably assessed; however, the concentration of protofibrils contains a marginal error (as protofibrils do not 
have the same molar extinction coefficient as monomer). Therefore, another assay such as BCA can be used to increase the reliability of 
protofibril concentration determined by UV A280. In addition, we have also observed that Aβ concentrations below ≤20 µM are underes-
timated by the UV A280 method than by BCA (see below). The most likely reason for this is the scarcity of aromatic residues in the Aβ 
amino-acid sequence.
2. BCA: The majority of commercial kits for determining protein concentrations (such as the PIERCE BCA kit) include BSA for generating 
a standard curve. The concentration of protein in unknown samples is determined using this standard curve. We found that a BSA 
standard curve results in ~40–50% underestimation of Aβ concentration in the fractions, compared with a standard curve based on 
Aβ40 serial dilutions (supplementary Fig. 4b). Moreover, there was close correlation between Aβ concentration estimations by two 
assays, when we used a standard curve based on Aβ40 serial dilutions. Therefore, we encourage the use Aβ40 standard curve for Aβ 
concentration estimations and not BSA. In contrast to Aβ42, Aβ40 is soluble in many aqueous media and less prone to aggregation.  
A 200-µM Aβ40 stock solution can be used for 10 serial dilutions (5–200 µM) with only ~200 µl of Aβ40 stock needed for one assay. 
Accordingly, repeated freeze and thaw cycles can be avoided by aliquoting the stock solution (200 µl per aliquot) and thawing it on 
ice. Freezing and thawing Aβ may also introduce unwanted artifacts and interfere with the protein determination. To address this, we 
also carried out BCA assay on Aβ40 solutions, which were either freshly prepared or aliquoted and frozen. Data show that both fresh 
and frozen Aβ40 solutions yield comparable results by BCA (supplementary Fig. 4c). However, repeated freezing and thawing of the 
stock Aβ solution may introduce greater variablility and should be avoided.
3. Comparing AAA, BCA and UV280: Aβ concentration estimations by UV A280 or BCA may contain a marginal error due to some  
limitations posed by the basic principles of each of these assays. AAA, however, is free of such limitations and provides a  
quantitative estimate of concentration and is more reliable. A comparative analysis of the three methods mentioned is summarized  
in supplementary Figure 4a. Briefly, (i) BCA measurements were found to be ~10–20% higher than UV measurements (Aβ40 standard 
curve was used for BCA); and (ii) UV A280 measurements were ~10% higher than AAA measurements. This applied to both monomeric 
and protofibrillar fractions.
 Box 4 | DETERMINATIoN oF A CoNCENTRATIoN BY UV A280 nm
Aβ concentration determination by UV spectrophotometry is based on the Beer–Lambert law: c A d= ÷ ×e
In the equation above, ‘c’ denotes the molar concentration, ‘A’ is the UV absorbance at a particular wavelength, ‘ε’ is the molar extinc-
tion coefficient at that wavelength and ‘d’ is the path length of the UV cell. Keeping the path length as 1 cm (10 mm) and the molar 
extinction coefficient at 280 nm (ε280  =  1490 M − 1 cm − 1)86, the A280 of 1 mg ml − 1 Aβ is predicted to be 0.33. In terms of molar concen-
tration, this corresponds to ~221 µM Aβ42 and ~231 µM Aβ40.
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 pause poInt Protofibrillar fractions can also be analyzed 
by injection into a Superose 6 pc 3.2/30 column. The 
elution of protofibrils on a Superdex 75 pc 3.2/30 column 
provides a measure of protofibrillar content rather than 
size distribution. In contrast, on a Superose 6 pc 3.2/30, 
protofibrils elute as a broad peak in the void volume  +  
included volume, thus allowing for analysis of heterogeneity 
and progression of aggregation.
4| Elute the fraction at a flow rate of 0.05 ml min − 1 for  
60 min.
 crItIcal step Set the high pressure limit to 2.4 MPa 
(Superdex 75 pc 3.2/30) or 1.2 MPa (Superose 6 3.2/30).
 pause poInt Although the PDA detector monitors 
sample elution at a range of wavelengths (200–400 nm), for 
analytical purposes, A210–214 nm is adequate. Samples can also 
be eluted at flow rates of up to 0.1 ml min − 1, provided the 
maximum pressure limit recommended by the manufacturer is 
not exceeded. 
? troublesHootInG
Morphological characterization by teM ● tIMInG ~20 min 
for one sample
5| Deposit 2–10 µl of a sample containing Aβ on a formvar-coated TEM grid and let the sample droplet settle for ~60 s.
 crItIcal step Place Aβ samples on TEM grids as soon as possible after fractionation to be able to assess the aggregation 
state of the starting material.
 pause poInt If the sample is ≥20 µM, deposit between 2 and 5 µl; for samples  < 20 µM, deposit 5–10 µl. The grids can 
also be glow discharged, which improves subsequent sample deposition on the surface.
6| Remove excess solution by wicking the edge of the grid on a piece of blotting paper.
7| Deposit a 10-µl drop of 2% UA on the grid and let it settle for ~60 s
8| Remove excess solution by wicking the edge of the grid on a piece of blotting paper.
9| Gently vacuum dry the grid from the edges.
 crItIcal step Do not touch the grid with vacuum probe to avoid physical damage to the grid. Use the vacuum to produce 
an air current over the grid to evaporate the remaining liquid.
 pause poInt Grids can be placed in a storage box in a dry place. Storing in a desiccating chamber or box will help  
prevent moisture accumulation and sample degradation.
10| Acquire images on a CM10 TEM (or equivalent TEM), equipped with a CCD camera, operated at an acceleration voltage  
of 80–100 kV. 
? troublesHootInG
assessment of fibril formation kinetics by tht binding ● tIMInG ~10 min for one time point
11| For fibrillization studies, aliquot 350–500 µl of each Aβ fraction into two 1.5-ml sterile microtubes.
 crItIcal step The sample volume should be ≥300 µl in a 1.5 ml polypropylene sterile microtube. Smaller volumes  
generate more errors during different aggregation experiments. Tubes larger than 1.5 ml also pose a problem because of 
increased evaporation.
12| For ThT-binding measurements, mix 80 µl of 10 µM Aβ fraction with 10 µl of 100 µM ThT and 10 µl of 500 mM  
glycine–NaOH (pH 8.5) in one well of a 384-well black plate.
 crItIcal step Avoid generating air bubbles as they will interfere optically with fluorescence signal acquisition.
 pause poInt This step is described for a final concentration of Aβ of ~10 µM, a ThT:Aβ ratio ≥1 and a final glycine–NaOH 
concentration of 50 mM. The step can be modified to accommodate different concentrations of Aβ. For example, for a sample 
table 6 | Preparation of Aβ fractions for neuronal toxicity 
assessment.
components stock Volume (µl)
Aβ fraction — 893.8
NaCl 2M 3.6
Amino acids in H2O 100× 10.0
Vitamins 100× 10.0
Amino acids in HCl 100× 10.0
Inorganic salts 100× 10.0
HEPES 100× 10.0
Pen-strep 100× 10.0
Glucose 1 M 25.0
Phenol red 0.5% 1.6
NaOH 1 M 7.0 (final pH 
7.3–7.5)
Sodium bicarbonate 1 M 26.0
Total volume 1,000 µl
Abbreviations: HEPES, (4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid; Pen–Strep,  
Penicillin–streptomycin.
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of 50-µM Aβ, either dilute the sample with sample buffer to 10-µM and proceed as above or use 70 mM glycine–NaOH  
stock-solution (20 µl Aβ  +  70 µl glycine–NaOH  +  10 µl ThT (100 µM)). Each sample should be assayed at least twice.
13| Acquire ThT fluorescence values using an Analyst AD fluorometer or a comparable fluorescence plate reader using an 
excitation wavelength of λ450 nm and an emission wavelength of λ485 nm.
14| Close the lids of microtubes and incubate at 37 °C without agitation in a Precision incubator.
 pause poInt Acquire ThT fluorescence data for 96 h at 24 h intervals or as desired.
 crItIcal step Briefly vortex the fractions before acquiring ThT fluorescence at each time point. 
? troublesHootInG
assessment of toxicity in primary neuronal cultures ● tIMInG ~1 h–5 d (depending on the assays used)
15| On days 5–7 after cell plating, Aβ fractions from SEC are mixed with components of a modified neurobasal media  
(table 6). Cultured neurons are exposed to various Aβ aggregates by removing all the media and adding 0.4 ml per well of 
the SEC fraction mixed with modified neurobasal media.
 pause poInt The eluate from the SEC will not sustain the viability of the cultured brain cells. Therefore, TC components need 
to be mixed with SEC fractions to correct sodium and potassium levels, provide energy and provide the correct pH. Standard 
TC medium can be purchased, but SEC fractions might be low in Aβ concentration, thus necessitating minimal further dilution 
of the SEC fraction by TC media. To accommodate this, modified neurobasal media are used to add TC components in minimal 
volumes (table 3). Neurobasal medium was developed to specifically support neurons79. Using this formulation, TC components 
can be varied for experimental purposes. The TC components should be added to SEC fractions shortly before application to cells.
16| Remove media from neuronal cultures and replace with Aβ fractions containing TC components and place the cells back 
in a 37 °C incubator with 5% CO2.
17| After 1 h to 5 d, assess the effects of Aβ treatment on neurons using biochemical methods such as LDH release assay 
and/or immunocytochemistry methods. LDH is a cytosolic enzyme that is primarily released on loss of integrity of the cell 
membrane and is a reliable indicator of cell death. The LDH release is proportional to the number of dead cells that can be 
measured in the culture medium. Alternatively, neurons plated on glass coverslips can be fixed and stained with antibodies 
to detect changes in neuronal architecture. The LDH release assay cannot detect cell loss, nor can it detect minor structural 
changes that may have important repercussions for the function of the neuron. Loss of synaptic connections would render a 
neuron as dysfunctional as neuronal death. The antibodies used here can also distinguish between changes in the dendritic 
(MAP2) versus axonal (NF-M) compartments.
(a) lDH release assay to determine cell death
 (i) Prepare 100 ml of buffer by adding one buffer tablet to 100 ml of distilled water.
 (ii)  Prepare LDH diaphorase solution by adding 150 µl of buffer and placing it on ice. 
 crItIcal step Extra solution can be frozen, but aliquoted to go through only one freeze–thaw cycle.
 (iii) Prepare LDH reaction solutions by adding 100 µl of the following four components to 9.6 ml of buffer.
(a) LDH diaphorase (see Step 17A(ii))
(b) NAD 100× (provided in the kit)
(c) Lactic acid 100× (provided in the kit)
(d) INT 100× (tetrazolium salt) (provided in the kit)
 (iv)  Prepare the LDH standard by diluting the vial included in the kit with 1.8 ml of buffer and placing immediately on ice. 
 crItIcal step The LDH standard is not stable and the remaining solution should be stored at  − 80 °C. The enzyme 
should only go through one freeze–thaw cycle.
 (v)  Dilute LDH standard in the ratio 1:20, 1:40, 1:80, 1:160 and 1:320, thus giving a standard curve of 10, 5, 2.5, 1.25 
and 0.75 mU ml − 1, respectively. 
 pause poInt 1 U of standard converts 1 µmol of substrate per min.
 (vi)  Set up a standard curve in a 96-well plate by adding 100 µl of standard to two or three wells for each concentration. 
Include a zero concentration by adding 100 µl of the buffer prepared in the first well. 
 crItIcal step If serum is used in an experiment, it will contain LDH and could interfere with the assay.
 (vii) Remove 100 µl of the medium from the experimental wells and transfer to the plate containing standards.
 (viii) Using the reaction solution prepared in Step 17A(iii), add 100 µl to each of the standard and experimental wells.
 (ix)  Shake for 30 min at RT. Using a 96-well microplate reader (TECAN safire 2 or any other suitable microplate reader), 
measure absorbance at λ490 nm. A standard curve of the LDH activity versus absorbance can be generated. The  
absorbance of the experimental sample can be used to determine LDH activity.
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 pause poInt The standard curve should be linear in the range of standards and the experimental samples should fall into 
this range. If not, higher samples must be diluted to bring them into the linear range of the standard curve.
 pause poInt The assay is based on Cayman Chemical Company’s LDH assay and is outlined for measuring all wells in a  
96-well plate. The assay for all standards and samples should be carried out either in duplicate or in triplicate. If more than 
one plate is needed, it is recommended to add standards to all plates that are being used.
(b) Immunocytochemical staining of neurons
 (i)  Fix cells in 4% paraformaldehyde in 0.15 M PO4 (Sorenson’s phosphate buffer plus 0.1% sodium azide) for 20 min. 
! cautIon Paraformaldehyde is toxic.
 (ii) Wash cells three times for 5 min each with phosphate buffer.
 (iii) Block the neurons with 10% FBS  +  0.3% Triton X-100 in 0.15 M PO4 for 1 h at RT.
 (iv) Wash three times for 5 min each with phosphate buffer.
 (v)  Dilute both primary antibodies in the ratio 1:500 in 0.15 M PO4, apply to cells and incubate for 1 h at RT. The MAP2 
and NF-M antibodies can be incubated together, as one is a monoclonal (raised in mouse) and the other is a polyclonal 
antibody (raised in rabbit).
 (vi) Wash three times for 5 min with phosphate buffer.
 (vii)  Dilute fluorescent secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 donkey anti-rabbit 
IgG) in 0.15 M PO4. Apply them onto the cells and incubate for 1 h at RT. 
 crItIcal step To avoid photobleaching the dye, cells should be kept in the dark during incubation and after washing.
 (viii)  Mount coverslips on slides with ProLong Gold mounting medium containing antifade reagent and the nuclei stain, DAPI. 
 pause poInt Antifade reagent helps suppress photobleaching. Coverslips are allowed to dry overnight, whereas 
plates can be assayed directly. 
 pause poInt Cultures can be visually monitored to determine when the experiment should be stopped depending 
on the response(s) of interest (for example, neuronal changes versus cell death). Small volumes of the medium can be 
tested from living cultures to determine whether cell death is occurring (such as by the release of LDH (Step 17A)). If 
the morphological changes in neurons are important, the entire medium at that time point is collected and the neu-
rons are immediately fixed and stained (Step 17B). Morphological changes can be seen using the Aβ40-Arctic peptide 
as early as 5 h, whereas Aβ40 wt peptide-induced cell loss could require 3–5 d.
? troublesHootInG
Troubleshooting advice can be found in table 7.
table 7 | Troubleshooting table.
step problem possible reason solution
1, 3 and 4 High column pressure 1. Precipitates or particulate matter 1. Ensure adequate peptide solubility and 
proper centrifugation to remove precipitates
2. Column not properly equilibrated and  
contains traces of ethanol or other buffer 
with high viscosity
2. Ensure proper column equilibration  
(2–3 CVs)
3. Aβ, or other hydrophobic peptides,  
sticking to the column from previous runs
3. Try extensive cleaning with 0.5 M NaOH
4. Very long ( > 10 cm) or narrow diameter 
PEEK tubing
4. Use tubing of minimal length and 0.75 mm 
internal diameter
5. Column matrix is degenerating 5. Use new columns or try extensive cleaning 
with 0.5 M NaOH
5–10 Clustering of Aβ aggregates 
on TEM grid
Decreased hydrophilicity of carbon coating; 
contamination with organic molecules etc.
The TEM grids should be treated with glow 
discharge before sample application
11–14 ThT values become stationary 
or decrease after initial risea
1. Lower than critical Aβ concentration for 
fibrillization
1. Check the Aβ concentration in samples 
and use a higher concentration, if too low, 
than that initially estimated
2. Increased evaporation from the tube,  
or low sample volume
2. Use a sample volume that leaves at least 
100–200 µl at the end of measurement
3. Clustering of fibrils, reducing the access  
of ThT to binding sites on fibrils
3. Vortex and/or sonicate in a water bath 
briefly (~30 s) before the assay
Abbreviations: Aβ, amyloid-β; CV, column volume; TEM, TEM, transmission electron microscopy; ThT, Thioflavin-T.
aThis can also be a normal phenomenon, if free A monomers are scarce and no further elongation of fibrils is taking place.
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● tIMInG
Step 1, Fractionation of Aβ by SEC: ~3–4 h (~1–2 h column equilibration, ~15 min solubilization and centrifugation and  
~1–2 h fractionation)
Step 2, Aβ concentration determination: ~10 min by UV spectrophotometry and ~ 45 min by BCA
Steps 3 and 4, Analytical SEC: ~1 h for one sample
Steps 5–10, TEM: ~20 min for one sample (~5 min for preparing the grid and ~15 min for image acquisition)
Steps 11–14, ThT binding: ~10 min for one time point
Steps 15–17, Assessment of toxicity in neuronal cultures: ~ 1 h–5 d (depending on the assays used)
antIcIpateD results
This paper describes a step-by-step method, principally based on SEC, for generating preparations of Aβ monomers and 
protofibrils, as well as fibrils, from various Aβ peptide sequences. This method has been used extensively by our group and 
by many other researchers in the field to elucidate Aβ amyloid formation, investigate the nature of the toxic Aβ species and 
develop amyloid-based diagnostic tools and therapeutic strategies for AD. This paper provides a convenient reference for 
the AD research community for reliable preparation and isolation of these different Aβ aggregate states for structural and 
functional studies.
preparation and characterization of 
monomeric a
Fractionation. Lyophilized Aβ peptides, 
obtained from different sources, are easily 
solubilized using 6-M guanidine hydrochlo-
ride, and the resultant solution contains 
predominantly monomeric Aβ (Fig. 3). 
Insoluble preexisting aggregates, if 
present, are effectively removed with brief 
centrifugation (≥16,000g, ~10 min). When 
this guanidine hydrochloride solution of Aβ 
is injected into a Superdex 75 HR 10/30 
SEC column, the peptide elutes as a single 
peak in the included volume of SEC column 
(0.45–0.55 CV for Superdex 75 HR 10/30; 
elution volume 11–13 ml) correspond-
ing to predominantly monomeric Aβ  
(Fig. 3a—red line). Generally, 1 mg of 
Aβ40 or Aβ42 (~80% net weight) dissolved 
in 1 ml of guanidine hydrochloride yields 
~2 ml at final concentrations of ~50–80 µM. 
Previous translational diffusion measure-
ments of these Aβ elution fractions, by 
pulse field gradient solution phase NMR, 
showed that Aβ predominantly elutes as a 
monomer80. The presence of a small amount 
of LMW oligomers (dimers, trimers, and so 
on), which exist in rapid equilibrium with 
the monomer, has been suggested and can-
not be ruled out53,73. However, these oligo-
meric species do not seem to accumulate 
or exist in stable forms, unless stabilized 
by chemical crosslinking17.
characterization. Reinjection of purified 
monomers into a Superdex 75 pc 3.2/30 
SEC analytical column showed a single 
elution peak and confirmed that the 
fractions corresponded to monomeric (M) 
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Figure 3 | SEC fractionation and biophysical characterization of A42 monomers and protofibrils.  
(a) Fractionation of A42 into protofibrillar (black line—using DMSO solubilization method) or monomeric 
(M) fractions (red line; using 6 M guanidine hydrochloride solubilization method) on a Superdex 75 HR 
10/30 SEC column. (b) Analytical SEC (Ana-SEC) of protofibrillar (black line) and monomeric A42 (red 
line; using 6 M guanidine hydrochloride solubilization method) on a Superdex 75 pc 3.2/30 SEC column. 
(c) Statistical analysis of the mean peak area for the elution of protofibrils and monomeric A42 (using 
DMSO solubilization method) on a Superdex 75 HR 10/30 SEC column from previous 25 injections. For each 
injection, the total (PF + M) peak area was expressed as 100% (n = 25; PF:M ratio = 52:48; % s.d. from  
the mean = PF (0.8–18) and M (0.1–13)). (d) Statistical analysis of the mean peak area for the elution  
of monomer from SEC purified protofibrils, after re-injection into a Superdex 75 pc 3.2/30 for Ana-SEC, 
from previous 20 injections. For each injection, the total (PF + M) peak area was expressed as 100%  
(n = 20; PF:M ratio = 79:21; % s.d. from the mean = PF (0.95–14) and M (0.05–13)). (e,f) Representative 
TEM images of monomeric A42 fractions soon after SEC (e) and fibrils formed by monomeric A42 after 
96 h of incubation at 37°C (10 μM A42, without agitation) (f). (g,h) Representative TEM images of A42 
protofibrils soon after SEC (g) and fibrils formed by A42 protofibrils after 96 h of incubation at 37 °C  
(10 μM A42, without agitation) (h). PF, protofibrils; M, monomeric A; scale bar, 200 nm.
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elution (Fig. 3b red line; peak around ~26 min). TEM analysis of monomeric fractions, soon after fractionation, confirmed the 
absence of any aggregated Aβ in these preparations (Fig. 3e) (monomeric Aβ is not detectable by TEM). Circular dichroism (CD) 
analysis followed by spectra deconvolution using CCA +  software Lincomb algorithm81,82 was carried out to assess the secondary 
structure elements of the Aβ fractions. CD analysis of this preparation showed a spectrum with minima at ~195–205 nm, consist-
ent with a predominantly random coil conformtion (supplementary Fig. 1a). Deconvolution of the spectrum suggested a mixture 
of predominantly (60%) random coil conformation and 39% β-turn structure. SDS-PAGE and the subsequent silver staining and/or 
western immunoblotting with 6E10 antibody showed that SEC-isolated monomeric Aβ40 migrated as a single band. In contrast, 
monomeric Aβ42 fractions migrated as a mixture of monomers, dimers and trimers, with monomer being the predominant species 
under similar conditions of electrophoresis (supplementary Fig. 1b). Previous studies have suggested that this anomalous migra-
tion of Aβ42 on SDS gels is a result of SDS-induced Aβ oligomerization because of the effect of SDS micelle formation and high local 
concentration of Aβ in micelles73. In addition, it is also possible that Aβ42 at higher than critical concentrations, and because of 
its high aggregation tendency, exists in equilibrium with LMW oligomers (dimers, trimers and low n-mers) seen on the gels53,73.
Briefly, the SEC method outlined above ensures that the starting material of the experiment is predominantly monomeric Aβ, 
free of protofibrillar or fibrillar aggregates and can be obtained in solutions free of organic solvents and compatible with cell 
culture manipulations. The extent of oligomerization and the amount of LMW oligomers formed is strongly dependent on the 
Aβ peptide sequence, the Aβ concentration and the incubation temperature and time. Therefore, we recommend the immediate 
use of SEC fractions or the maintenance of samples at 4 °C until use. Although we have not observed significant protofibril 
formation by TEM and ThT binding, when these solutions are stored at 4 °C for up to 24 h (supplementary Fig. 3c,i), we 
cannot rule out that the oligomerization and formation of LMW oligomers take place under these conditions. This is especially 
critical when Aβ42 and Aβ42/Aβ40-Arctic mutant (E22G) are used and stored at concentrations  > 50 µM. Therefore, we recom-
mend that peptide solutions be prepared freshly before performing the experiments, maintained at 4 °C and used within a few 
hours ( < 3–5 h). If the experimental setup and conditions do not allow for rapid preparation and the immediate use of the 
monomeric Aβ fractions, we recommend that the samples be stored at 4 °C. To ensure the absence of fibrillar or protofibrillar 
aggregates at the time of using a stored sample, a small aliquot can be centrifuged and evaluated by Ana-SEC, ThT and TEM.
preparation and characterization of a42 protofibrils
Fractionation. To generate protofibrils of Aβ42, or Aβ sequences with a high aggregation tendency (like Aβ-Arctic), the  
peptide is solubilized using the DMSO method18 (Step 1B). This method is very effective in yielding a solution enriched with 
protofibrils of broad size distribution18; however, this preparation also contains a significant amount of monomeric Aβ that 
must be separated from the protofibrils. Fractionating this preparation on a Superdex 75 HR 10/30 SEC column yields two  
elution peaks separated by ≥2 ml of elution volume. The first peak corresponding to the void volume (~7–9 ml of elution  
volume for the HR 10/30 columns) is enriched with protofibrils (PF), whereas the second elution peak corresponds to  
monomeric (M) Aβ42 (Fig. 3a, black line). When 1 mg of Aβ42 (~80% net weight) is solubilized using the DMSO method  
(860 µl of total solution) and fractionated as mentioned, the typical yield is as follows: PF ~2 ml, ~40–60 µM of final Aβ  
concentration and M ~2 ml, ~40–50 µM of final Aβ concentration.
reproducibility of fractionation. Generally, when Aβ42 is solubilized in DMSO and fractionated, the PF peak area and height are 
almost always greater than the M peak, but the absolute values are not identical from one injection to another. To illustrate 
this, analysis of Aβ42 protofibrillar preparations (using the DMSO method), carried out by three different individuals in our 
group over the past 2–3 years, is presented in Figure 3c. The data show that there is occasional variation between the extent 
of PF and M elution. For each injection, the combined (PF  +  M) peak area was expressed as 100%. The percentage (%) mean 
peak area for PF and M elution was calculated and the results confirmed that the usual trend of Aβ42 elution is PF > M  
(the mean peak area ratio of PF to M  =  52:48; % s.d. from mean: PF  =  0.8–18, M  =  0.1–13; n = 25). For Aβ40 or other less-
aggregation-prone Aβ sequences, the M elution almost always predominates (supplementary Fig. 1f). Despite these slight  
variations, structural analysis of Aβ42 PF and M fractions did not exhibit any drastic differences (data not shown). However, 
these different elution patterns produce variations in the concentration of Aβ fractions.
characterization. Protofibrils were obtained as described above and subjected to further analysis. TEM analysis of the protofibril 
fractions showed aggregates of various morphologies including curvilinear aggregates ( < 200 nm long) and small spherical 
structures (Fig. 3g). These observations were consistent with previously described morphologies for protofibrils12,13.  
Protofibrils, on reinjection into an Ana-SEC (a Superdex 75 pc 3.2/30 column), elute predominantly in the void elution  
volume (Fig. 3b, black line; peak height around ~19 min). Interestingly, in addition to void volume elution, we consistently 
observe an additional small peak corresponding to the monomer elution. This could be due to either the reestablishment of 
monomer-protofibril equilibrium, monomer dissociation due to interactions with the chromatography matrix or a combination 
of both. To determine whether this monomer peak was consistent and also whether there was a variation in this peak from 
one protofibril preparation to another, we carried out statistical analysis of 20 Ana-SEC elution profiles of Aβ42 protofibrils. 
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The analysis was based on reinjection of purified protofibrils on independent occasions and using different preparations. For 
each reinjection, the combined (PF  +  M) peak area was expressed as 100% and the percentage (%) mean peak area for PF 
and M elution was calculated. The data presented in Figure 3d show that SEC-purified protofibrils, when reinjected into a 
Superdex 75 pc 3.2/30 column, predominantly elute in the void volume, with a small elution peak corresponding to mono-
meric elution (mean peak area PF:M  =  79:21; % s.d. from mean: PF  =  0.95–14, M  =  0.05–13; n = 20).
The fractions were then subjected to CD spectroscopy for analysis of secondary structure elements. CD spectra deconvolu-
tion, carried out using the CCA +  software Lincomb algorithm81,82, showed that the protofibrils, obtained using this protocol, 
consisted of 43% β-sheet, 38% α-helix and 5% random coil as secondary structure elements (supplementary Fig. 1a). These 
values for the secondary structure elements were similar as reported previously for Aβ40 protofibrils and show that proto-
fibrils consist of mixed α-helical-β-sheet structural elements14,20.
Similar to protofibrils of synthetic Aβ40 (ref. 14), Aβ42 protofibrils are SDS-labile and run as multiple bands (monomer to  
trimer), along with a high-molecular-weight smear, by SDS-PAGE (supplementary Fig. 1b), despite the fact that these  
species elute in the void volume of Superdex 75 ( > 70 kDa), which should only contain PFs. This anomalous migration on  
SDS gels by protofibrils and oligomers of sAβ has also been reported by other groups13,83. There are different possibilities to 
explain these experimental observations; (i) some of these LMW oligomers may exist in rapid equilibrium with protofibrils; 
(ii) these oligomers may not exist in solution but form as a result of SDS-induced disassociation of protofibrils; or  
(iii) formation of these species may be induced by the interaction of Aβ with SDS micelles as described above73.
SDS-stable Aβ oligomers have been consistently observed in naturally secreted Aβ preparations obtained from the condi-
tioned media of Chinese hamster ovary cells, overexpressing wt APP or APP-bearing fAD mutations19,55. These species migrate 
predominantly as dimers and trimers on SDS-PAGE and have been proposed as bona fide oligomers19. However, these spe-
cies are distinct from the oligomeric forms described above, because they were shown to be stable and did not disassociate 
after treatment with formic acid, heating or incubation with chemical denaturants (guanidine hydrochloride). Furthermore, 
naturally secreted oligomers have not been shown to undergo further oligomerization and fibril formation. Although chemical 
modifications and/or covalent cross-linking of monomeric Aβ species could explain the kinetic stability and lack of fibrilliza-
tion by these oligomers, direct evidence for such modifications by mass spectrometry or by other tools remains lacking.
Fibrillization studies
To study the aggregation and kinetics of fibril formation, purified Aβ42 PF and M fractions were separately incubated  
(~10 µM) at 37 °C without agitation and allowed to fibrillize. Consistent with previous reports13, we observed that PF  
fractions showed a less pronounced rise in ThT binding over time, compared with M fractions (supplementary Fig. 1c). TEM 
analysis, after 96 h of incubation, revealed that although in the case of monomeric fraction elongated intertwining fibrils 
were formed (Fig. 3f), the PF fraction contained a substantial amount of elongated protofibrils interspersed among fibrils  
(Fig. 3h). The slow fibrillization of protofibrils is consistent with the proposed mechanism of fibril formation by monomer 
addition, rather than annealing and/or self-assembly of protofibrillar aggregates20,21. Indeed, addition of monomeric Aβ  
to protofibrillar fractions accelerates their fibrillization21.
preparation and characterization of a40 protofibrils
Aβ40 protofibrils can be generated in a consistent manner by dissolving the peptide in NaOH and rapidly moving the highly 
acidic TFA salt peptide through its isoelectric point to a pH of 7.2 − 7.6 (ref. 14). Incubating the peptide at 500 µM in  
PBS (pH 7.4) for 2–3 d at RT generates monomers and protofibrils, which vary around a PF:M ratio in the range of 40–60% 
(ref. 14). The progression of protofibril formation can be quantitatively monitored on a daily basis by injecting small aliq-
uots of the stock solution into a Superdex 75 HR 10/30 SEC column or into an analytical Superdex 75 pc 3.2/30 column. 
Before injecting into an SEC column, the sample is briefly centrifuged (16,000g for 10 min at 4 °C) to remove any fibrils 
that might have formed during the incubation. This is usually indicated by the appearance of a pellet after the centrifuga-
tion. TEM analysis of the pellet obtained in this procedure revealed that they are predominately made of fibrils14. Regard-
ing the SEC elution profile, the protofibril peak appears first in the void volume (~7–9 ml for HR 10/30 columns) and can 
be collected in 0.5–1-ml fractions with Aβ concentrations ranging from 10 to 40 µM. TEM images of this protofibril peak 
showed small spheres, ~4–6 nm in diameter with a variation in length, and curvilinear structures  < 200 nm in length and 
~4–6 nm in width14. The CD spectrum of these fractions showed a broad negative ellipticity between 225 and 208 nm, 
consistent with the presence of a mixture of random coil, α-helix and β-sheet structures14. Estimation of the secondary 
structure contents of the CD spectra, performed using the CDANAL program82 and the Brahms and Brahms reference library84, 
showed that these protofibril preparations contain 47% β-sheet, 40% random coil and 13% α-helix secondary structure  
elements20. In addition, the protofibril peak was found to bind Congo red and ThT similarly, but to a lesser extent, than mature 
fibrils14,20. The protofibril fractions can be combined (~1–2 ml) or analyzed separately depending on the concentration of 
peptide and solution volume needed. The monomer peak emerges in the included volume, as mentioned above, and can 
yield similar concentrations as the protofibril peak. TEM analysis of monomer fractions confirmed the aggregate-free nature 
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of the preparation14,20. SDS-PAGE, followed by western blot-
ting analysis, for monomer fractions, showed a single 4-kDa 
band; however, the protofibrillar fractions migrated as a 
mixture of multiple bands with molecular weights corre-
sponding to species from monomer to tetramer14. The latter 
observation suggested that Aβ40 protofibrils were not SDS 
stable and migrated as LMW bands on SDS gels.
application to a faD mutants
The methods described above for wt Aβ (Aβ40 and Aβ42) 
solubilization and fractionation are also useful for prepara-
tion of different monomeric and protofibril fractions of fAD 
Aβ mutants. We have used this protocol to isolate the  
monomeric and protofibrillar forms of Aβ40-Arctic (E22G), 
Aβ40-Dutch (E22Q) and Aβ40-Flemish (A21G) peptides. 
Figure 4 summarizes the results of these studies. Aβ40- 
Arctic (E22G) exhibits faster aggregation kinetics than does 
wt Aβ40 and has a higher tendency to form and accumulate 
protofibrils18,36,85. Accordingly, we found that dissolving syn-
thetic Aβ40-Arctic in DMSO (Step 1B) resulted in a solution 
that is highly enriched with protofibrils and monomeric Aβ. 
Fractionation of this solution on a Superdex 75 HR 10/30 
column showed that the predominant elution peak was in the 
void volume (Fig. 4a, black line) and contained aggregates of 
heterogeneous morphologies including curvilinear and spheri-
cal assemblies (Fig. 4e). The fibrillization studies revealed 
that Aβ40-Arctic formed high ThT-binding fibrils, both from 
solution containing monomeric or protofibrillar Aβ40-Arctic 
(Figs. 2h and 4b, only fibrils from the monomeric fraction 
are shown). Using the DMSO solubilization method, the yield 
of Aβ40-Arctic is similar to that of Aβ42 protofibrils (2 ml; 
~40–60 µM). Previous efforts to generate Aβ40-Arctic protofi-
brils, using the NaOH solubilization method, resulted in only 
10–40 µM for similar volumes18. Therefore, we recommend 
using the DMSO solubilization method (Step 1B) for generat-
ing Aβ40-Arctic protofibrils. The Aβ40-Dutch (E22Q) mutant 
exhibited a similar SEC elution pattern as the wt Aβ42  
(Fig. 4a, red line); however, these protofibrils formed fibrils 
only at concentrations ≥20 µM (Figs. 2i and 4c). Finally, 
Aβ40-Flemish (A21G) also eluted as two peaks correspond-
ing to a protofibrillar and monomeric species (Fig. 4a, green line), but neither was shown to form fibrils over the time course 
of the experiment (96 h incubation at 37 °C, without agitation) (Figs. 2j and 4d). These observations are in accordance with 
previously published reports showing that Arctic (E22G) and Dutch (E22Q) mutations in Aβ significantly increase fibril  
nucleation and growth, whereas the Flemish (A21G) mutation decreases fibril growth85.
application to ra peptides and synthetic peptides from other sources
Next, we sought to determine whether this protocol for generation of monomeric and protofibrillar Aβ fractions is equally  
applicable to synthetic (sAβ) and recombinant forms (rAβ) of Aβ obtained from different sources. For this purpose, we ob-
tained synthetic Aβ42 (as TFA salt) from Bachem (Switzerland, cat. no. H-1368). rAβ peptides were purchased from a commer-
cial source (rPeptides, Bogart, GA, USA) and were also donated generously by two independent research groups (Carl Frieden, 
Washington University, St. Louis, USA and Rudolf Glockshuber, ETH, Zurich, Switzerland). Further, the rAβ42 peptides from 
rPeptides were provided as either TFA (cat. no. A-1002-2) or NaOH (cat. no. A-1165-2) salts, thus allowing us to determine 
whether different counterions affect the extent of protofibril formation. All sAβ and rAβ peptides were solubilized using the 
DMSO method and fractionated on a Superdex 75 HR 10/30 column. Synthetic and recombinant Aβ42 eluted as protofibrillar 
and monomer peaks (Fig. 5a,b), and TEM analysis of the protofibrillar fractions showed predominantly curvilinear and spheri-
cal morphologies (Fig. 5c–f).
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Figure 4 | Application to fAD-associated A mutant peptides. (a) SEC 
fractionation of DMSO solubilized A40-Arctic (black line), A40-Dutch (red 
line) and A40-Flemish (green line) on a Superdex 75 HR 10/30 column. 
(b–d) Fibril formation by protofibrillar and monomeric A40-Arctic (b), A40-
Dutch (c) and A40-Flemish (d) assessed by ThT binding assay (10 μM A;  
96 h, 37 °C without agitation). (e–j) TEM analysis of SEC isolated protofibrils 
of A40-Arctic (e), A40-Dutch (f) and  A40-Flemish (g). (h–j) TEM analysis 
of fibrils or non-fibrillar aggregates formed by 10 monomeric A40-Arctic (h), 
A40-Dutch (i) and A40-Flemish (j) after 96 h incubation (10 M A, 37 °C, 
without agitation). PF, protofibrils; M, monomeric A; a.u., arbitrary units; 
the error bars in (b–d) represent s.d. in duplicate samples; scale bar, 200 nm.
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Recombinant Aβ40 peptides also eluted in an identical man-
ner as synthetic Aβ40 (Keck facility), as a predominant single 
elution peak in the included volume and as a small peak in the 
void volume (supplementary Fig. 1f–g). These observations 
show that the protocol outlined above is applicable to Aβ 
peptides from synthetic and recombinant sources. However, it 
is noteworthy that protofibrils are a heterogeneous population 
of aggregates and it is quite likely that the size distribution 
among protofibrils might not be identical for Aβ prepared in 
different methods (synthetic and recombinant).
subfractionation of a42 protofibrils and aggregated a42
Further separation of protofibrils of different sizes can be 
achieved using columns with different separation capacities 
or combining multiple columns with extended separation 
ranges (table 2) (for example, the Superose 6 HR 10/30 
column by itself (supplementary Fig. 2) or a Superose 6 
HR 10/30 column connected in series to a TSK-GEL 4,000 
SEC column). Generally, this procedure yields from four to 
six protofibril fractions (1 ml each), but only the first and 
last fractions differ significantly in terms of size and mor-
phology distribution. For example, we previously showed 
that fractionation of the protofibril peak, obtained from 
a 1:1 solution mixture of Aβ-Arctic and Aβ40 wt, using a 
Superose 6 column, yielded seven protofibril fractions18. 
Only fraction 7 was highly enriched in annular Aβ struc-
tures, with a molecular weight distribution centered around 
150–250 kDa. The remaining fractions were heterogeneous 
and exhibited a molecular weight distribution of 80–880 
kDa18. We have observed that the addition of monomers 
of a slow aggregating sequence (e.g., Aβ40) to a highly 
amyloidogenic sequence (e.g., Aβ42 (ref. 21) and Aβ40-
Arctic18) results in kinetic stabilization of the protofibrils formed by the more amyloidogenic sequence. This strategy can be 
exploited to stabilize protofibrils and facilitate their purification18.
stability of the preparation
Considering the situations in which fractionation is not immediately possible, or when protofibrils are not used within a day 
after fractionation or samples need to be sent to another location, we sought to determine the stability of the protofibrillar 
preparation over time. To study this, we solubilized synthetic Aβ42 (1 mg ml − 1, using the DMSO method) and either injected 
(250 µl) into a Superdex 75 column immediately after solubilization (and centrifugation) or left the solution at 4 °C for a 
duration of up to 24 h. At 4 and 24 h, the solution was centrifuged and injected (250 µl). We observed that the protofibrillar 
peak area increased by ~10–15%, as compared with time 0, with a corresponding decline in the monomer peak area  
(supplementary Fig. 3a). A TEM analysis of the crude (CR) stock solution after 4 h of incubation at 4 °C revealed  
predominantly protofibrillar structures and did not show any fibrils (supplementary Fig. 3d,g). Although the peptide loss 
due to fibril formation, if any, was minimal, we do not recommend storage of the stock solution for more than 2–4 h.
Similarly, SEC-isolated protofibril fractions (1 ml, ~50 µM) were also incubated at 4 °C for 24 h. Comparison of sample  
reinjection, soon after fractionation and after 24 h of incubation at 4 °C, showed that the predominant elution was in the void 
volume (% total peak area: PF  =  80–86, M  =  14–20) (supplementary Fig. 3b). TEM analysis, after 24 h of incubation at 4 °C, 
did not show any mature fibrils; however, protofibrils seemed to cluster with extended incubation (supplementary Fig. 3e,h).
preparation of a fibrils
The majority of structural and toxicity studies have compared the properties of monomeric and protofibrillar Aβ with that of 
Aβ fibrils. Aβ fibrils can be generated using purified monomeric preparations or CR Aβ preparations, i.e., those that contain a 
mixture of monomeric and protofibrillar species, depending on the quantity of fibrils desired and the experimental conditions 
used. Both methods yield fibrils of similar ThT binding and morphologies.
For highly aggregation-prone sequences (e.g., Aβ42 wt or Aβ40-Arctic), fibrils can be obtained by incubating monomeric Aβ 
(10–50 µM) at 37 °C under mild agitation for 24–48 h (Figs. 3f and 4h, respectively, for Aβ42 WT or Aβ40-Arctic). Aβ40 fibril 
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Figure 5 | Application to synthetic and recombinant A peptides.  
(a) Comparison of recombinant A42 (rA42; black line) and synthetic A42 
(sA42; red line) fractionation into protofibrillar and monomeric Ab fractions 
on a Superdex 75 HR 10/30 SEC column. The peptides were solubilized using 
DMSO at concentrations of: 0.5 mg ml−1 (rA42) and 1 mg ml−1 ( sA42). 
(c,e) Representative TEM images of rA42 protofibrils (c) and sA42 
protofibrils (e). (e) Comparison of recombinant rA42, provided as TFA (red 
line) or NaOH (black line) salts. The peptides were solubilized with DMSO at 
1 mg ml−1, and fractionated on a Superdex 75 HR 10/30 SEC column.  
(d,f) Representative TEM images of  rA42-TFA protofibrils (d) and rA42-NaOH 
protofibrils (f). Scale bar, 200 nm.
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formation, from SEC-isolated monomeric 
Aβ40, requires concentrations ≥50 µM  
and agitation for 24–48 h21. These 
conditions result in the formation of 
mature amyloid fibrils with an average 
diameter of 8–12 nm. The fibrils are 
characterized by high ThT binding and 
TEM analysis, and shows an extensive 
network of intertwining  > 1-µm-long 
filamentous morphologies.
Fibrils can also be prepared from 
high concentrations of CR Aβ prepara-
tions (1–2 mg ml − 1 of Aβ solutions 
containing monomers, protofibrils and 
a small amount of fibrils) obtained 
using one of the methods described 
for generating protofibrils (the DMSO 
or NaOH method). Concentrated stock 
solutions are incubated at 37 °C, under 
mild agitation, for 24 h. This method 
generates high ThT-binding fibrils with 
morphologies similar to those obtained 
when using purified monomeric Aβ 
(supplementary Fig. 1d,e). Preparing 
fibrils from CR mixtures allows for ob-
taining fibrils in a short time span and 
for the generation of large quantities 
of fibrils for use in high-throughput 
screening or in vivo studies. Therefore, 
we recommend the latter method only 
if experiments demand substantial 
quantities of fibrils.
sec-isolated a fractions are toxic to 
cultured neurons
Initial studies showing the neuro-
toxic nature of protofibrils used Aβ40 
protofibrils isolated by SEC using a 
Sephadex G75 column14,20. Applica-
tions of ~20 µM protofibrils produced 
massive cell loss over a 5 d period, as 
measured by LDH (Fig. 6a)14. This was 
supported by cytological observations showing loss of neuronal processes and cell bodies (Fig. 6b)14. A concern with cell 
culture experiments is that the aggregation state of Aβ can change with extended incubation periods ( > 2–6 h), depending 
on the concentration of the peptide. Cell culture media were collected after 5 d and no fibrils could be observed in either 
the monomer or protofibril-treated cultures14. This suggested that fibrils were not killing the neurons and some Aβ species 
preceding fibril formation were toxic. Interestingly, similar neuronal death was observed with monomeric fractions after 
10–24 h of treatment as the protofibril preparation (Fig. 6a)14, suggesting that monomer fractions can form nonfibrillar Aβ 
aggregates during the course of the experiment, which might have contributed and/or caused toxicity. Instantaneous readout 
such as the MTT assay or electrophysiology has confirmed that protofibrils have their own inherent biological activity14,20. In 
support of the soluble Aβ aggregates causing neurotoxicity, preparations of disaggregated Aβ40-Arctic peptide purified by SEC 
were found to produce rapid toxicity65. Aβ40-Arctic induced neuronal loss, but observations at earlier time points (within 5 h) 
showed morphological changes in neuronal dendrites and axons, which preceded the rise in LDH (Fig. 6c)65. Similarly, isolat-
ing monomeric Aβ42 and applying it to primary neocortical cultures produced a loss of neuronal process (Fig. 6e) that was 
almost identical to that of Aβ40-Arctic (Fig. 6d). These findings support the concept that prefibrillar aggregates of Aβ induce 
synaptic failure, which precedes overt cell loss. These data show the value and versatility of SEC to generate different Aβ 
preparations in order to probe the pathophysiological relevance of various aggregation states in AD.
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Figure 6 | Neurotoxicity of SEC-purified A monomers and protofibrils. (a,b) Time course of wild-type 
A40–induced injury: A40 was incubated at 500 M in PBS for 3 d at RT, and then centrifuged to 
remove fibrils. The monomeric and protofibril fractions were isolated by SEC using a Superdex 75 10/30 
column. The monomeric (LMW) and protofibril (PF) peaks were collected in 0.5-ml fractions to which 
modified neurobasal medium was added, and then placed on primary cerebral cortical cultures. (a) 
Neuronal loss was measured by LDH release into the culture medium every 24 h. Each monomeric and 
protofibril peak was collected in 5 individual fractions and A concentration was measured in each. 
Control LDH release (no A added) is listed as “0” under fibrils and given a value of 1. (b) Neurons were 
exposed to medium only (i), monomeric A (18 M) (ii), protofibrils (21 M) (iii), or  fibrils (20 M for 
5 d) (iv), and then cultures were preserved and stained with microtubule associated protein-2 (MAP2) to 
identify neurons (dark blue staining). (c,d) Time course of A40-Arctic–induced injury: A40-Arctic was 
solubilized using 6 M guanidine hydrochloride and fractionated on a Superdex 75 10/30 column. Modified 
neurobasal medium was added to the monomeric fractions (A diluted to 20-M concentration). (c) 
Quantitative results of the immunocytochemical staining and biochemical measurements of LDH release. 
Statistically significant loss of neuronal process is observed by 7 h, whereas the release of LDH was not 
significant until 15 h. Data is reproduced with copyright approval65. (d) Immunocytochemical staining of 
primary cerebral cortical neurons treated with monomeric A40-Arctic at time 0 (i), show a progressive 
neurodegeneration with initial loss of dendrites by MAP2 staining (red) and axons by NF-M staining 
(green) at 10 h (ii) followed by cell loss at 24 h (iii). (e) Time course of A42-induced injury: A42 was 
solubilized using 6 M guanidine HCl solubilization method and fractionated on a Superdex G75 10/30 
column. Modified Neurobasal media was added to the monomeric fractions. Neurons, on coverslips, were 
treated with A42 (22.5 M). At 9.5- and 20-h time periods, coverslips were removed, fixed and stained 
for Neurofilament N, an axon-specific protein. (i) Healthy neurons receiving no A42 for 20 h; (ii) 
Neurons losing neuronal process as early as 9.5 h; (iii) Further neuronal loss observed at 20 h. The time 
course of neurite loss with A42 was very similar to the findings with A40-Arctic in d.
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Note: Supplementary information is available via the HTML version of this article.
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